66. IgA腎症 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 349 / 薬物数 : 251 - (DrugBank : 75) / 標的遺伝子数 : 43 - 標的パスウェイ数 : 152
薬物、開発者(Primary Sponsor)、臨床試験情報(症例登録開始年(Enrollment year)、フェーズ、ID、実施国)
A-623 or AMG 623
Anthera Pharmaceuticals, Inc
2014 Phase 2;Phase 3 EUCTR2014-001365-26-CZ Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;United Kingdom
Anthera pharmaceuticals, Inc
2015 - EUCTR2014-001365-26-SE Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom
2015 - EUCTR2014-001365-26-IT Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
2015 - EUCTR2014-001365-26-HU Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
2015 Phase 2;Phase 3 EUCTR2014-001365-26-ES Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
2015 Phase 2;Phase 3 EUCTR2014-001365-26-DE Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom
A07ea06
CROWN OY
2012 - EUCTR2012-001923-11-IT Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Abelmoschus manihot
Chen Xiangmei
2014 Phase 4 NCT02231125 China
ACE inhibitor
Yonsei University
2016 Phase 4 NCT02981212 Korea, Republic of
ACE inhibitor or angiotensin receptor antagonist
Peking University First Hospital
2016 - NCT03015974 China
ACE/ARB
Mayo Clinic
2009 Phase 4 NCT00498368 United States
Acei
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
Ningxia Medical University General
2024 Phase 0 ChiCTR2400083794 China
St. Joseph's Hospital and Medical Center, Phoenix
2002 Phase 3 NCT00318474 United States
The First Affiliated Hospital of Zhejiang University
2009 - ChiCTR-TRC-09000338 China
The First Hospital, Peking University
2006 - ChiCTR-TRC-06000004 China
the Second Affiliated Hospital Zhejiang University School of Medicine
2024 Phase 2 ChiCTR2400079954 China
Acei/ARB and corticosteroids
Chulalongkorn University
2012 Phase 4 NCT02571842 Thailand
Acth (acthar) GEL
Mayo Clinic
2015 Phase 3 NCT02282930 United States
Acthar 80 unit injection
Baylor College of Medicine
2015 Phase 4 NCT02382523 United States
Acthib - polvere E solvente PER soluzione iniettabile 1 flaconcino polvere+1 siringa preriempita solvente 0.5 ML
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
ADX-097
Q32 Bio Inc.
2024 Phase 2 NCT06419205 United States
Aliskiren
Chinese University of Hong Kong
2009 Phase 3 NCT00870493 Hong Kong
Columbia University
2009 Phase 4 NCT01129557 United States
Kagawa University
2010 Phase 4 NCT01184599 Japan
The University of Hong Kong
2009 Phase 4 NCT00922311 China
Allopurinol
Sun Yat-sen University
2007 - NCT00793585 China
ALN-CC5
Alnylam Pharmaceuticals Inc
2019 Phase 2 EUCTR2018-002716-27-SE Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2019 Phase 2 EUCTR2018-002716-27-GB Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2019 Phase 2 EUCTR2018-002716-27-ES Australia;Canada;France;Germany;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
ALXN1210
ALEXION PHARMACEUTICALS INCORPORATED
2021 Phase 2 EUCTR2020-001537-13-IT Australia;Belgium;Canada;France;Germany;Italy;Korea, Democratic People's Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Alexion Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-001537-13-SE Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-FR Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-ES Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-DE Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Dr. Alfons Segarra Medrano
2022 Phase 4 EUCTR2021-005609-28-ES Spain
ALXN2050
Alexion Pharmaceuticals, Inc.
2022 Phase 2 EUCTR2021-001426-22-DE Argentina;Australia;Brazil;China;Germany;Israel;Italy;Korea, Republic of;Mexico;Peru;Serbia;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
Ambrisentan
Peking University First Hospital
2024 Phase 3 ChiCTR2400080435 China
Angiotensin
Assistance Publique - Hôpitaux de Paris
2018 Phase 3 NCT03188887 France
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
Angiotensin blockade
The University of Hong Kong
2002 Phase 4 NCT00863252 China
Angiotensin II
Japanese Study Group of Multiple drug therapy for IgAN
2004 - JPRN-C000000341 Japan
ANTI-CD19/bcma CAR NK cells
Jieyang People's Hospital
2025 Early Phase 1 NCT06926985 China
APL-2
Apellis Pharmaceuticals, Inc.
2018 Phase 2 NCT03453619 United States
ARB
ARB therapeutic society of IgA nephropathy
2003 Phase 4 JPRN-C000000380 Japan
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
Ningxia Medical University General
2024 Phase 0 ChiCTR2400083794 China
The First Affiliated Hospital of Zhejiang University
2009 - ChiCTR-TRC-09000338 China
The First Hospital, Peking University
2006 - ChiCTR-TRC-06000004 China
Yonsei University
2016 Phase 4 NCT02981212 Korea, Republic of
the Second Affiliated Hospital Zhejiang University School of Medicine
2024 Phase 2 ChiCTR2400079954 China
ARO-C3
Arrowhead Pharmaceuticals
2022 Phase 1/Phase 2 NCT05083364 Australia;Georgia;Germany;Korea, Republic of;New Zealand;Spain;Thailand;United Kingdom
ARO-CFB
Arrowhead Pharmaceuticals
2024 Phase 1/Phase 2 NCT06209177 New Zealand
Artesunate
Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine
2020 Phase 0 ChiCTR2000038104 China
AT-1501
Eledon Pharmaceuticals
2022 Phase 2 NCT05125068 Australia;Croatia;Malaysia;New Zealand;Philippines;Poland;Spain;Sri Lanka;Thailand;United Kingdom
Eledon Pharmaceuticals, Inc
2022 Phase 2 EUCTR2021-004795-34-PL Australia;China;Croatia;Malaysia;New Zealand;Philippines;Poland;Spain;Sri Lanka;Thailand
2022 Phase 2 EUCTR2021-004795-34-ES Australia;China;Croatia;Malaysia;New Zealand;Philippines;Poland;Spain;Sri Lanka;Thailand
Atacicept
Israni Rubeen
2024 Phase 3 JPRN-jRCT2031230629 Argentina;Australia;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;India;Ireland;Italy;Japan;Malaysia;Philippines;Poland;Portugal;Singapore;South Korea;Spain;Sri Lanka;Taiwan;Thailand;Turkey;United Kingdom;United States
Merck KGaA
2017 Phase 2 EUCTR2016-002262-31-GB Belgium;Czech Republic;France;Israel;Italy;Japan;Korea, Republic of;Singapore;Spain;Taiwan;United Kingdom;United States
Vera Therapeutics, Inc.
2023 Phase 3 NCT04716231 Australia;Belgium;Canada;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2022 Phase 2 EUCTR2020-004892-41-PL Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-GR Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-DE Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-BE Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
Atacicept 150 MG
Merck Biopharma Co., Ltd.
2017 Phase 2 JPRN-jRCT2080223899 Europe;Japan
Vera Therapeutics, Inc.
2024 Phase 2 NCT06674577 United States
Atacicept 25 MG
EMD Serono Research & Development Institute, Inc.
2017 Phase 2 NCT02808429 Germany;Japan;United Kingdom;United States
Merck Biopharma Co., Ltd.
2017 Phase 2 JPRN-jRCT2080223899 Europe;Japan
Atacicept 75 MG
EMD Serono Research & Development Institute, Inc.
2017 Phase 2 NCT02808429 Germany;Japan;United Kingdom;United States
Merck Biopharma Co., Ltd.
2017 Phase 2 JPRN-jRCT2080223899 Europe;Japan
ATG-F
Centre Hospitalier Universitaire de Saint Etienne
2011 Phase 4 NCT02523768 France
Atrasentan
CHINOOK THERAPEUTICS, U.S., Inc
2021 Phase 3 EUCTR2020-003084-26-IT Argentina;Australia;Brazil;Canada;China;Czech Republic;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Chinook Therapeutics U.S., Inc.
2022 Phase 3 EUCTR2020-003084-26-PT Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2022 Phase 3 EUCTR2020-003084-26-IE Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Taiwan;United States
2021 Phase 3 EUCTR2020-003084-26-PL Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2021 Phase 3 EUCTR2020-003084-26-FR Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Taiwan;United Kingdom;United States
2021 Phase 3 EUCTR2020-003084-26-DE Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2021 Phase 3 EUCTR2020-003084-26-CZ Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Chinook Therapeutics, Inc.
2020 Phase 3 NCT04573478 Argentina;Australia;Brazil;Canada;China;Colombia;Czechia;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Fukui Tomoaki
2021 Phase 3 JPRN-jRCT2071210028 Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Hong Kong;India;Italy;Japan;New Zealand;Poland;South Korea;Spain;Taiwan;United Kingdom;United States
Novartis Pharmaceuticals
2023 Phase 2 NCT06841094 Australia;Brazil;Korea, Republic of;Malaysia;Spain;United States
2023 Phase 2 NCT05834738 Australia;Brazil;Korea, Republic of;Malaysia;Spain;United States
2021 Phase 2 NCT04573920 Australia;Italy;Korea, Republic of;Spain;United Kingdom;United States
Avacopan
Mayo Clinic
2025 Phase 2 NCT06676579 United States
AVB-S6-500
Aravive, Inc.
2019 Phase 2 NCT04042623 United States
Azathioprine
A. Manzoni Hospital
1999 Phase 3 NCT01392833 -
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
Azilsartan
Chinese Cardiovascular Association-HX Fund
2023 Phase 4 ChiCTR2300076082 China
Bardoxolone methyl capsules
Reata, a wholly owned subsidiary of Biogen
2017 Phase 2 NCT03366337 United States
BCX9930 hydrochloride
BIOCRYST PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-005855-19-IT France;Germany;Hungary;Italy;Spain;United Kingdom
BioCryst Pharmaceuticals Inc
2022 Phase 2 EUCTR2020-005855-19-HU France;Germany;Hungary;Italy;Romania;Spain;United Kingdom
2021 Phase 2 EUCTR2020-005855-19-ES France;Germany;Hungary;Italy;Spain;United Kingdom
Belimumab
University of Leicester
2019 Phase 2 EUCTR2017-004366-10-GB United Kingdom
Benlysta
University of Leicester
2019 Phase 2 EUCTR2017-004366-10-GB United Kingdom
Bexsero - sospensione iniettabile - USO intramuscolare - siringa preriempita (vetro) - 0.5ML - 1 siringa preriempita CON AGO
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
BIO-kult advanced
University of Leicester
2023 - NCT06767592 United Kingdom
BION-1301
Chinook Therapeutics, Inc.
2023 Phase 3 NCT05852938 Argentina;Australia;Belgium;Brazil;Canada;China;Croatia;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Spain;Taiwan;Turkey;United Kingdom;United States
BION-1301 multiple doses
Novartis Pharmaceuticals
2019 Phase 1/Phase 2 NCT03945318 Korea, Republic of;United Kingdom;United States
BION-1301 single dose
Novartis Pharmaceuticals
2019 Phase 1/Phase 2 NCT03945318 Korea, Republic of;United Kingdom;United States
Blisibimod
Anthera Pharmaceuticals
2014 Phase 3 NCT02052219 -
2013 Phase 2/Phase 3 NCT02062684 Canada;Czech Republic;Czechia;Germany;Hong Kong;Italy;Korea, Republic of;Malaysia;Philippines;Russian Federation;Singapore;Spain;Taiwan;Thailand;United Kingdom
Blisibimod injection
Anthera Pharmaceuticals, Inc
2014 Phase 2;Phase 3 EUCTR2014-001365-26-CZ Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;United Kingdom
Anthera pharmaceuticals, Inc
2015 - EUCTR2014-001365-26-SE Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom
2015 - EUCTR2014-001365-26-IT Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
2015 - EUCTR2014-001365-26-HU Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
2015 Phase 2;Phase 3 EUCTR2014-001365-26-ES Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
2015 Phase 2;Phase 3 EUCTR2014-001365-26-DE Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom
Blood sample
Centre Hospitalier Universitaire de Saint Etienne
2012 - NCT02526966 France
BNJ441
Alexion Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-001537-13-SE Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-ES Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-DE Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Bortezomib
Ruijin Hospital
2022 - NCT05383547 China
The Rogosin Institute
2010 Phase 4 NCT01103778 United States
Budesonide
CALLIDITAS THERAPEUTICS AB
2020 Phase 3 EUCTR2020-003308-14-IT Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-IT Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom
CROWN OY
2012 - EUCTR2012-001923-11-IT Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Calliditas Therapeutics AB
2021 Phase 3 EUCTR2020-003308-14-FI Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-003308-14-BE Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-SE Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-PL Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-GR Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-GB Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-FR Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-CZ Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-SE Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-PL Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-GB Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-FI Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-ES Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-CZ Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-BE Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Pharmalink AB
2013 - EUCTR2012-001923-11-ES Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-SE Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-NL Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-GB Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-FI Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-DK Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-DE Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-CZ Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-BE Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2005 Phase 2 NCT00767221 Sweden
The First Affiliated Hospital of Air Force Medical University
2025 - ChiCTR2500103064 China
The First Affiliated Hospital,Sun Yat-sen University
2025 - ChiCTR2500097089 China
C09
RETROPHIN, INC
2018 Phase 3 EUCTR2017-004605-41-IT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Calcitriol
Chinese University of Hong Kong
2006 Phase 4 NCT00319761 Hong Kong
Osaka University Hospital Department of nephrology
2007 - JPRN-UMIN000002474 Japan
Yonsei University
2011 - NCT01237028 Korea, Republic of
CCX168
Amgen
2015 Phase 2 NCT02384317 Sweden;United States
ChemoCentryx, Inc.
2015 Phase 2 EUCTR2014-003402-33-SE Belgium;Sweden;United States
2015 Phase 2 EUCTR2014-003402-33-BE Belgium;Sweden;United States
Cemdisiran
Alnylam Pharmaceuticals
2019 Phase 2 NCT03841448 Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Alnylam Pharmaceuticals Inc
2019 Phase 2 EUCTR2018-002716-27-SE Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2019 Phase 2 EUCTR2018-002716-27-GB Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2019 Phase 2 EUCTR2018-002716-27-ES Australia;Canada;France;Germany;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Chinese herb prescription granule plus prednisone
Shanghai University of Traditional Chinese Medicine
2010 - NCT01879514 China
Cilazapril
The First Hospital, Peking University
2006 - ChiCTR-TRC-06000004 China
CM313
Keymed Biosciences Co.Ltd
2025 Phase 2 NCT06830395 -
CM338
Keymed Biosciences Co.Ltd
2023 Phase 2 NCT05775042 China
Continue their usual therapy
Sun Yat-sen University
2007 - NCT00793585 China
Corticosteroid
Peking University First Hospital
2016 - NCT03015974 China
Yonsei University
2016 Phase 4 NCT02981212 Korea, Republic of
Corticotherapy
Assistance Publique - Hôpitaux de Paris
2018 Phase 3 NCT03188887 France
Creatinine
Affiliated Hospital of North Sichuan Medical College
2024 Phase 0 ChiCTR2500098584 China
Cyclophosphamid
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
Cyclophosphamide
Peking University First Hospital
2016 - NCT03015974 China
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
The First Affiliated Hospital of Air Force Medical University
2025 - ChiCTR2500103064 China
the First Affiliated Hospital of Zhengzhou University
2024 Phase 4 ChiCTR2400083736 China
Dapagliflozin
Daping Hospital, Army Medical University
2023 Phase 4 ChiCTR2300067263 China
Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
2022 Phase 3 EUCTR2021-006854-29-IT Italy
Shenzhen People's Hospital
2024 Phase 1 ChiCTR2400088054 China
Travere Therapeutics, Inc.
2018 Phase 3 NCT03762850 Australia;Belgium;Croatia;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Decortin H
Universitätsklinikum Ulm
2008 - EUCTR2007-000443-99-DE Germany
Dihuang
Zhejiang Provincal Hospital of Traditional Chinese Medicine
2021 Phase 0 ChiCTR2100042331 China
Dipyridamole
Peking University First Hospital
2016 - NCT03015974 China
2013 - ChiCTR-TRC-13003038 China
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
2001 - JPRN-C000000363 Japan
1998 - JPRN-C000000374 Japan
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
1998 - JPRN-C000000375 Japan
Enalapril
ARB therapeutic society of IgA nephropathy
2003 Phase 4 JPRN-C000000380 Japan
National Center for Research Resources (NCRR)
2000 - NCT00006137 -
Enalapril valsartan methylprednisone
Hospital Britanico
1996 Phase 4 NCT00367562 Argentina
Fecal microbiota transplantation
Air Force Military Medical University, China
2017 Phase 2 NCT03633864 China
Felzartamab
Biogen
2025 Phase 3 NCT06935357 United States
HI-Bio, A Biogen Company
2021 Phase 2 NCT05065970 Australia;Belgium;Bulgaria;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
Human Immunology Biosciences, Inc
2021 Phase 2 EUCTR2020-005054-19-DE Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-CZ Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-BG Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
MorphoSys AG
2021 Phase 2 EUCTR2020-005054-19-ES Australia;Belgium;Bulgaria;Canada;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-BE Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
Finerenone
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2022 - NCT06460987 China
Zhejiang University
2024 Phase 3 NCT06580288 -
FOS
St. Joseph's Hospital and Medical Center, Phoenix
2002 Phase 3 NCT00318474 United States
Fostamatinib 100 MG
Rigel Pharmaceuticals
2014 Phase 2 NCT02112838 Austria;Germany;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib 100 MG tablet
Rigel Pharmaceuticals Inc
2014 Phase 2 EUCTR2014-000331-16-GB Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
2014 Phase 2 EUCTR2014-000331-16-AT Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib 150 MG
Rigel Pharmaceuticals
2014 Phase 2 NCT02112838 Austria;Germany;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib 150 MG tablet
Rigel Pharmaceuticals Inc
2014 Phase 2 EUCTR2014-000331-16-GB Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
2014 Phase 2 EUCTR2014-000331-16-AT Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib disodium
Rigel Pharmaceuticals Inc
2014 Phase 2 EUCTR2014-000331-16-GB Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
2014 Phase 2 EUCTR2014-000331-16-AT Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib disodium tablet 100 MG
Rigel Pharmaceuticals
2015 Phase 2 NCT02433236 -
Fostamatinib disodium tablet 150 MG
Rigel Pharmaceuticals
2015 Phase 2 NCT02433236 -
Gastrus
Uppsala University Hospital
2013 - NCT01781312 Sweden
Glucocorticoid
Ruijin Hospital
2024 - NCT06654596 China
West China Hospital of Sichuan University
2025 - ChiCTR2500096335 China
the First Affiliated Hospital of Zhengzhou University
2024 Phase 4 ChiCTR2400083736 China
Glucose
Assistance Publique - Hôpitaux de Paris
2018 Phase 3 NCT03188887 France
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
GSK1550188
University of Leicester
2019 Phase 2 EUCTR2017-004366-10-GB United Kingdom
GUT-directed budesonide and SOC
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
Haemophilus influenzae
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Henagliflozin
Peking University First Hospital
2024 Phase 3 ChiCTR2400080435 China
Hiberix - polvere E solvente PER soluzione iniettabile PER USO intramuscolare 1 flaconcino DI polvere + 1 siringa preriempita DI solvente DA 0.5 ML
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
High DOSE-VIS649
Visterra, Inc.
2020 Phase 2 NCT04287985 Australia;Canada;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sri Lanka;Taiwan;Thailand;United Kingdom;United States
HR19042 capsule
Jiangsu HengRui Medicine Co., Ltd.
2023 Phase 1 NCT06922305 China
2021 Phase 1 NCT04887532 China
HR19042 capsules
Jiangsu HengRui Medicine Co., Ltd.
2021 Phase 2 NCT05016323 China
HRS-5965
Chengdu Suncadia Medicine Co., Ltd.
2023 Phase 2 NCT06137768 China
HRS-5965 capsules
Chengdu Suncadia Medicine Co., Ltd.
2024 Phase 1 NCT06490991 China
HRS-5965 tablets
Chengdu Suncadia Medicine Co., Ltd.
2024 Phase 1 NCT06490991 China
HS-10390
Hansoh BioMedical R&D Company
2024 Phase 2 NCT06635772 China
HS-10390 tablet
Hansoh BioMedical R&D Company
2023 Phase 1 NCT05942625 China
HSK39297 100mgbid
Haisco Pharmaceutical Group Co., Ltd.
2024 Phase 2 NCT06670352 China
HSK39297 200mgqd
Haisco Pharmaceutical Group Co., Ltd.
2024 Phase 2 NCT06670352 China
HSK39297 50mgbid
Haisco Pharmaceutical Group Co., Ltd.
2024 Phase 2 NCT06670352 China
Human soluble recombinant FC-gamma receptor IIB
Baxalta Innovations GmbH
2015 - EUCTR2015-002345-64-CZ Belgium;Canada;Czech Republic;Denmark;Germany;Hong Kong;Sweden;United Kingdom;United States
Hydroxychloroquine
Department of Pharmacy, Drum Tower Hospital Affiliated to Nanjing University Medical School
2021 Phase 1 ChiCTR2100052910 China
Peking University First Hospital
2021 Phase 0 ChiCTR2100045306 China
Shanxi Medical University Second Hospital
2024 Phase 4 ChiCTR2400093530 China
Hydroxychloroquine and SOC
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
Hydroxychloroquine oral tablet
Centre Hospitalier Universitaire de Saint Etienne
2025 Phase 2 NCT06350630 France
Hydroxychloroquine sulfate
LLiu
2015 Phase 4 NCT02351752 China
Peking Union Medical College Hospital
2016 Phase 4 NCT02765594 China
Peking University First Hospital
2016 Phase 2 NCT02942381 China
Immune suppressant
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2022 - NCT06460987 China
Immunosuppressants
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
2019 Phase 2/Phase 3 NCT03418779 China
The Second Hospital of Shanxi Medical University
2024 - ChiCTR2400083991 China
Tianjin Hospital
2023 - ChiCTR2500101762 China
Immunosuppressive treatment
Yonsei University
2019 Phase 4 NCT03468972 Korea, Republic of
Inhibace/cozaar
Peking University
2006 - NCT00378443 -
Intensive supportive care
Yonsei University
2019 Phase 4 NCT03468972 Korea, Republic of
Intervention FOR incipient patients AT LOW risk OF disease progression
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2020 - NCT04438603 China
Intervention FOR patients AT high risk OF disease progression
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2020 - NCT04438603 China
Intravenous rituximab
Chulalongkorn University
2012 Phase 4 NCT02571842 Thailand
Mayo Clinic
2009 Phase 4 NCT00498368 United States
Ionis-FB-LRX
Ionis Pharmaceuticals, Inc.
2019 Phase 2 NCT04014335 Australia;Canada;New Zealand;Singapore
Iptacopan
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
Novartis Pharma AG
2023 Phase 3 EUCTR2020-002200-40-FR Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-CZ Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-FR Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
2021 Phase 3 EUCTR2020-001049-38-CZ Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2020 Phase 3 EUCTR2020-001049-38-HU Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
2020 Phase 3 EUCTR2020-001049-38-FI Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2019 Phase 2 EUCTR2017-000891-27-CZ Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-SE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-NL Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-FI Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-DK Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-DE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2017 Phase 2 EUCTR2017-000891-27-GB Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Pharmaceuticals
2025 Phase 2 NCT06797518 -
Iptacopan hydrochloride
Novartis Pharma AG
2022 Phase 3 EUCTR2020-002200-40-DK Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2020-001049-38-SK Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2020-001049-38-SI Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-NO Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-NL Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-DE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-BE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-SE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-NO Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-NL Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-DK Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-BE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2020 Phase 3 EUCTR2020-001049-38-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
Irbesartan
AZIENDA OSPEDALIERA PROVINCIALE DI LECCO
2005 - EUCTR2005-003885-40-IT Italy
Hansoh BioMedical R&D Company
2024 Phase 2 NCT06635772 China
Sun Yat-sen University
2007 Phase 3 NCT00657059 China
Travere Therapeutics, Inc.
2018 Phase 3 NCT03762850 Australia;Belgium;Croatia;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Yueyang Integrated Traditional Chinese and Western Medicine Hospital, Affiliated with Shanghai University of Traditional Chinese Medicine
2024 Phase 1 ChiCTR2400082620 China
Irbesartan tablets (approved IN THE USA. reference listed drug avapro) NDC # 43547-0374-03
Retrophin, Inc.
2018 Phase 3 EUCTR2017-004605-41-GB Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-ES Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States
KP104
Kira Pharmacenticals (US), LLC.
2025 Phase 2 NCT05517980 -
Leflunomide
Chinese General Hospital of PLA
2010 - ChiCTR-TRC-10000776 China
The First Affiliated Hospital of Chengdu Medical College
2018 - ChiCTR1800019606 China
Leflunomide 20 MG+prednisone 0.5MG/KG/D
Shenzhen Second People's Hospital
2019 Phase 4 NCT04020328 China
Lisinopril
Japanese Study group of Kidney Disease in Children
2005 - JPRN-C000000006 Japan
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
1998 - JPRN-C000000373 Japan
LNP023
Novartis Pharma AG
2023 Phase 3 EUCTR2020-002200-40-FR Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2020-002200-40-DK Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2020-001049-38-SK Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2020-001049-38-SI Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-NO Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-NL Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-DE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-CZ Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-BE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-SE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-NO Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-NL Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-FR Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
2021 Phase 3 EUCTR2020-001049-38-DK Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-CZ Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-BE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2020 Phase 3 EUCTR2020-001049-38-HU Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
2020 Phase 3 EUCTR2020-001049-38-FI Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2020 Phase 3 EUCTR2020-001049-38-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2019 Phase 2 EUCTR2017-000891-27-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2019 Phase 2 EUCTR2017-000891-27-HU Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2019 Phase 2 EUCTR2017-000891-27-FR Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2019 Phase 2 EUCTR2017-000891-27-CZ Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-SE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-NL Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-FI Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-DK Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-DE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-BE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2017 Phase 2 EUCTR2017-000891-27-GB Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Pharmaceuticals
2021 Phase 3 NCT04578834 Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Puerto Rico;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
2021 Phase 3 NCT04557462 Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
2018 Phase 2 NCT03373461 Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Norway;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
LNP023 hydrochlori
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
Losartan
Chen Xiangmei
2014 Phase 4 NCT02231125 China
Fukuoka University Faculty of Medicine
2009 - JPRN-UMIN000002887 Japan
Hu Qianqian
2018 Phase 0 ChiCTR2200058382 China
Japanese Study group of Kidney Disease in Children
2005 - JPRN-C000000006 Japan
Jiujiang Hospital of Traditional Chinese Medicine
2023 Phase 0 ChiCTR2200066983 China
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
2023 Phase 2 ChiCTR2400094993 China
The First Hospital, Peking University
2006 - ChiCTR-TRC-06000004 China
The Third Xiangya Hospital of Central South University
2018 Phase 4 study ChiCTR-IIR-17013487 China
LOW antigen content diet
Uppsala University Hospital
2010 - NCT01203007 Norway;Sweden
LOW DOSE-VIS649
Visterra, Inc.
2020 Phase 2 NCT04287985 Australia;Canada;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sri Lanka;Taiwan;Thailand;United Kingdom;United States
MASP-2 antibody, OMS00620646, OMS620646
Omeros Corporation
2021 Phase 3 EUCTR2018-000075-33-GR Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-SK Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-SE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-PL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-LT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-BG Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-BE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
Medium DOSE-VIS649
Visterra, Inc.
2020 Phase 2 NCT04287985 Australia;Canada;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sri Lanka;Taiwan;Thailand;United Kingdom;United States
Menatetrenone
Osaka University Hospital Department of nephrology
2007 - JPRN-UMIN000002474 Japan
Menveo - polv.E soluz.PER soluz. iniett.-USO intramuscolare-comp. coniug.liofilizz.mena:flac.(vetro) comp. goniug.liqui.mencwy:flac.(vetro)-1 flac+1flac
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Metformin
West China Hospital of Sichuan University
2025 - ChiCTR2500096335 China
Methylprednisolon
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
Methylprednisolone
A. Manzoni Hospital
1999 Phase 3 NCT01392833 -
Mayo Clinic
2025 Phase 2 NCT06676579 United States
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
Sixth Affiliated Hospital, Sun Yat-sen University
2021 Phase 3 NCT04833374 China
Sun Yat-sen University
2014 Phase 2 NCT02160132 China
2007 Phase 3 NCT00657059 China
The George Institute
2012 - NCT01560052 Australia;Canada;China;Hong Kong;India;Malaysia
Zhongshan Hospital of Fudan University
2008 - ChiCTR-TRC-09000607 China
Methylprednisolone mylan GéNérique
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2017 Phase 3 EUCTR2016-004507-31-FR France
Methylprednisolone pulse
Peking University First Hospital
2016 Phase 2/Phase 3 NCT02647255 China
West Japan Study Group for Therapy of IgA Nephropathy
2006 - JPRN-UMIN000000593 Japan
the First Affiliated Hospital of Zhengzhou University
2024 Phase 4 ChiCTR2400083736 China
Methylprednisolone succinate
Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
2022 Phase 3 EUCTR2021-006854-29-IT Italy
Metilprednisolone sodio succinato
Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
2022 Phase 3 EUCTR2021-006854-29-IT Italy
Mezagitamab
Nishizawa Atsushi
2022 Phase 1 JPRN-jRCT2011220009 Australia;Belgium;China;Hungary;Italy;Japan;Serbia;Singapore;South Korea;Spain;Taiwan;UK;USA
Takeda
2025 Phase 3 NCT06963827 -
2022 Phase 1 NCT05174221 Australia;Belgium;China;Hungary;Italy;Japan;Korea, Republic of;Serbia;Singapore;Spain;Taiwan;United Kingdom;United States
Mizoribine
Japanese Study Group of Multiple drug therapy for IgAN
2004 - JPRN-C000000341 Japan
Nanjing general hospital of Nanjing military command
2011 - ChiCTR-ONC-10001124 China
Peking University First Hospital
2013 - ChiCTR-TRC-13003038 China
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
2001 - JPRN-C000000363 Japan
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
1998 - JPRN-C000000375 Japan
West Japan Study Group for Therapy of IgA Nephropathy
2006 - JPRN-UMIN000000593 Japan
MMF
Second Xiangya Hospital of Central South University
2014 Phase 3 NCT02187900 China
St. Joseph's Hospital and Medical Center, Phoenix
2002 Phase 3 NCT00318474 United States
Sun Yat-sen University
2007 Phase 3 NCT00657059 China
Zhongshan Hospital of Fudan University
2008 - ChiCTR-TRC-09000607 China
MOR03087
Human Immunology Biosciences, Inc
2021 Phase 2 EUCTR2020-005054-19-DE Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-CZ Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-BG Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
MorphoSys AG
2021 Phase 2 EUCTR2020-005054-19-ES Australia;Belgium;Bulgaria;Canada;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-BE Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
MOR202
Human Immunology Biosciences, Inc
2021 Phase 2 EUCTR2020-005054-19-DE Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-CZ Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-BG Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
MorphoSys AG
2021 Phase 2 EUCTR2020-005054-19-ES Australia;Belgium;Bulgaria;Canada;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-BE Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
MY008211A tablets
Wuhan Createrna Science and Technology Co., Ltd
2024 Phase 2 NCT06687174 China
Mycophenolat-natrium
Universitätsklinikum Ulm
2008 - EUCTR2007-000443-99-DE Germany
Mycophenolate mofetil
Nanjing University School of Medicine
2003 - NCT00301600 China
Peking University First Hospital
2016 - NCT03015974 China
Second Xiangya Hospital of Central South University
2014 Phase 3 NCT02187900 China
St. Joseph's Hospital and Medical Center, Phoenix
2002 Phase 3 NCT00318474 United States
Sun Yat-sen University
2007 Phase 3 NCT00657059 China
The First Affiliated Hospital of Air Force Medical University
2025 - ChiCTR2500103064 China
The University of Hong Kong
2002 Phase 4 NCT00863252 China
Yonsei University
2016 Phase 4 NCT02981212 Korea, Republic of
the First Affiliated Hospital of Zhengzhou University
2024 Phase 4 ChiCTR2400083736 China
Mycophenolate mofetil (MMF) and SOC
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
Mycophenolate mofetil plus lower dose OF prednisone
Zhi-Hong Liu, M.D.
2010 - NCT01269021 China
Mycophenolate sodium
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
2022 Phase 4 ChiCTR2200060990 China
UHB NHS Foundation Trust
2010 Phase 2 EUCTR2009-016003-26-GB United Kingdom
Mycophenolic acid
UHB NHS Foundation Trust
2010 Phase 2 EUCTR2009-016003-26-GB United Kingdom
Mycophenolic sodium
UHB NHS Foundation Trust
2010 Phase 2 EUCTR2009-016003-26-GB United Kingdom
Myfortic
Universitätsklinikum Ulm
2008 - EUCTR2007-000443-99-DE Germany
Myfortic 180MG tablets
UHB NHS Foundation Trust
2010 Phase 2 EUCTR2009-016003-26-GB United Kingdom
Myfortic 360MG tablets
UHB NHS Foundation Trust
2010 Phase 2 EUCTR2009-016003-26-GB United Kingdom
Narsoplimab
Omeros Corporation
2021 Phase 3 EUCTR2018-000075-33-GR Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-SK Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-SE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-PL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-LT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-BG Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-BE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2016 Phase 2 NCT02682407 Hong Kong;United States
Nefecon
CALLIDITAS THERAPEUTICS AB
2020 Phase 3 EUCTR2020-003308-14-IT Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-IT Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom
CROWN OY
2012 - EUCTR2012-001923-11-IT Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Calliditas Therapeutics AB
2021 Phase 3 EUCTR2020-003308-14-FI Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-003308-14-BE Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-SE Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-PL Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-GR Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-GB Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-FR Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-CZ Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 NCT03643965 Argentina;Australia;Belarus;Belgium;Canada;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-SE Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-PL Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-GB Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-FI Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-ES Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-CZ Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-BE Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Everest Medicines (Singapore) Pte. Ltd.
2022 Phase 3 NCT05534919 China
Pharmalink AB
2013 - EUCTR2012-001923-11-ES Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 NCT01738035 Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-SE Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-NL Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-GB Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-FI Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-DK Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-DE Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-CZ Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-BE Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Nefecon 16MG daily
Calliditas Therapeutics AB
2020 Phase 3 NCT04541043 Argentina;Australia;Belarus;Belgium;Canada;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
NM8074
NovelMed Therapeutics
2025 Phase 2 NCT06454110 -
NON-steroidal mineralocorticoid receptor antagonist and SOC
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
NTQ5082 capsules 100 MG
Nanjing Chia-tai Tianqing Pharmaceutical
2025 Phase 2 NCT06982040 -
NTQ5082 capsules 200 MG
Nanjing Chia-tai Tianqing Pharmaceutical
2025 Phase 2 NCT06982040 -
NTQ5082 capsules 300 MG
Nanjing Chia-tai Tianqing Pharmaceutical
2025 Phase 2 NCT06982040 -
Omega-3 fatty acid ethylester90
Kuhnil Pharmaceutical Co., Ltd.
2007 Phase 3 NCT00549692 Korea, Republic of
Omega-3 fatty acid fish OIL supplement
Mayo Clinic
2009 Phase 4 NCT00498368 United States
OMS721
OMEROS CORPORATION
2019 Phase 3 EUCTR2018-000075-33-IT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Korea, Democratic People's Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
Omeros Corporation
2021 Phase 3 EUCTR2018-000075-33-GR Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2019 Phase 3 EUCTR2018-000075-33-GB Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States
2019 Phase 3 EUCTR2018-000075-33-DE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 NCT03608033 Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-SK Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-SE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-PL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-LT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-HU Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-ES Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-CZ Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-BG Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-BE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-AT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Hungary;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;United States
2016 Phase 2 NCT02682407 Hong Kong;United States
OPL-CCL2-LPM
Osprey Pharmaceuticals USA, Inc.
2009 Phase 1 NCT00856674 Canada
Optimized supportive care
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
2019 Phase 2/Phase 3 NCT03418779 China
Oral prednisolone and SOC
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
OVER-encapsulated 150 MG irbesartan tablets
Retrophin, Inc.
2018 Phase 3 EUCTR2017-004605-41-ES Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States
OVER-encapsulated irbesartan tablets
RETROPHIN, INC
2018 Phase 3 EUCTR2017-004605-41-IT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Travere Therapeutics Inc.
2019 Phase 3 EUCTR2017-004605-41-PT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2019 Phase 3 EUCTR2017-004605-41-PL Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2019 Phase 3 EUCTR2017-004605-41-DE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-LT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-HR Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-EE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-CZ Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-BE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Paricalcitol
Chinese University of Hong Kong
2008 Phase 3 NCT00599963 China;Hong Kong
Pneumovax – soluzione iniettabile IN siringa preriempita DA 0,5 ML
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Potassium
Hu Qianqian
2018 Phase 0 ChiCTR2200058382 China
Jiujiang Hospital of Traditional Chinese Medicine
2023 Phase 0 ChiCTR2200066983 China
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
2023 Phase 2 ChiCTR2400094993 China
The Third Xiangya Hospital of Central South University
2018 Phase 4 study ChiCTR-IIR-17013487 China
Yueyang Integrated Traditional Chinese and Western Medicine Hospital, Affiliated with Shanghai University of Traditional Chinese Medicine
2024 Phase 1 ChiCTR2400082620 China
Prednisolon
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
Universitätsklinikum Ulm
2008 - EUCTR2007-000443-99-DE Germany
Prednisolone
Japanese Study Group of Multiple drug therapy for IgAN
2004 - JPRN-C000000341 Japan
Juntendo University
2018 - JPRN-UMIN000032031 Japan
Mayo Clinic
2025 Phase 2 NCT06676579 United States
Nephrology Department, Hangzhou Hospital of Traditional Chinese Medicine, Zhejiang Province
2019 Phase 0 ChiCTR1900026883 China
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
Sun Yat-sen University
2016 Phase 2/Phase 3 NCT02662283 China
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
2001 - JPRN-C000000363 Japan
1998 - JPRN-C000000374 Japan
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
1998 - JPRN-C000000375 Japan
UHB NHS Foundation Trust
2010 Phase 2 EUCTR2009-016003-26-GB United Kingdom
West Japan Study Group for Therapy of IgA Nephropathy
2006 - JPRN-UMIN000000593 Japan
Prednisolone plus cyclophosphamide
Air Force Military Medical University, China
2024 Phase 3 NCT05510323 China
Prednisone
A. Manzoni Hospital
1999 Phase 3 NCT01392833 -
Department of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine
2010 - ChiCTR-TRC-13003702 China
Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
2022 Phase 3 EUCTR2021-006854-29-IT Italy
Mayo Clinic
2025 Phase 2 NCT06676579 United States
Peking University
2006 - NCT00378443 -
Shanghai University of Traditional Chinese Medicine
2016 - NCT02712697 China
Sun Yat-sen University
2007 Phase 3 NCT00657059 China
The First Affiliated Hospital of Xi'an Jiaotong University Medical College
2010 - ChiCTR-TRC-10000824 China
The First Affiliated Hospital of Zhejiang University
2009 - ChiCTR-TRC-09000338 China
The First Hospital, Peking University
2006 - ChiCTR-TRC-06000004 China
Xijing hospital
2023 Phase 4 ChiCTR2300076949 China
Yancheng Third People's Hospital
2011 - ChiCTR-OPN-16010028 -
the First Affiliated Hospital of Zhengzhou University
2024 Phase 4 ChiCTR2400083736 China
Prednisone 5 MG
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2017 Phase 3 EUCTR2016-004507-31-FR France
Prednisone alone
Guangdong General Hospital
2016 Phase 4 NCT03218852 China
2012 Phase 4 NCT01758120 China
Prednisone and cyclophosphamide
Guangdong General Hospital
2016 Phase 4 NCT03218852 China
Prednisone arrow 20MG
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2017 Phase 3 EUCTR2016-004507-31-FR France
Prednisone arrow 5 MG
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2017 Phase 3 EUCTR2016-004507-31-FR France
Prednisone IN full dose
Zhi-Hong Liu, M.D.
2010 - NCT01269021 China
Prednisone or prednisolone
Nanjing University School of Medicine
2011 - NCT01451710 China
Prednisone plus cyclophosphamide
Guangdong General Hospital
2012 Phase 4 NCT01758120 China
Probiotics combined with enteric-coated budesonide capsule
Gang Xu
2024 Phase 4 NCT06528015 China
Probucol
Guangdong General Hospital
2007 Phase 4 NCT00426348 China
Proline
the Second Affiliated Hospital Zhejiang University School of Medicine
2024 Phase 2 ChiCTR2400079954 China
Protectis
Uppsala University Hospital
2013 - NCT01781312 Sweden
R935788
Rigel Pharmaceuticals Inc
2014 Phase 2 EUCTR2014-000331-16-GB Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
2014 Phase 2 EUCTR2014-000331-16-AT Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Ramipril
AZIENDA OSPEDALIERA PROVINCIALE DI LECCO
2005 - EUCTR2005-003885-40-IT Italy
Chinese University of Hong Kong
2002 Phase 3 NCT01225445 Hong Kong
The Chinese University of Hong Kong
2004 - ChiCTR-TRC-09000630 China
Rapamune
NEPHROLOGY DEPARTMENT (HOSPITAL UNIVERSITARY OF BELLVITGE)
2005 - EUCTR2005-002610-37-ES Spain
RAS
Assistance Publique - Hôpitaux de Paris
2018 Phase 3 NCT03188887 France
Tianjin Hospital
2023 - ChiCTR2500101762 China
RAS 2410
Nan Chen,MD
2020 Phase 4 NCT04525729 China
RAS inhibitor
Ruijin Hospital
2023 - NCT06589752 China
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2022 - NCT06460987 China
Ravulizumab
ALEXION PHARMACEUTICALS INCORPORATED
2021 Phase 2 EUCTR2020-001537-13-IT Australia;Belgium;Canada;France;Germany;Italy;Korea, Democratic People's Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Alexion Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-001537-13-SE Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-FR Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-ES Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-DE Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Dr. Alfons Segarra Medrano
2022 Phase 4 EUCTR2021-005609-28-ES Spain
RC18 160MG
RemeGen Co., Ltd.
2020 Phase 2 NCT04291781 China
RC18 240MG
RemeGen Co., Ltd.
2020 Phase 2 NCT04291781 China
RE-021
RETROPHIN, INC
2018 Phase 3 EUCTR2017-004605-41-IT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Retrophin, Inc.
2018 Phase 3 EUCTR2017-004605-41-GB Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-ES Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States
TRAVERE THERAPEUTICS, INC
2022 Phase 2 EUCTR2021-000621-27-IT France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
Travere Therapeutics Inc.
2019 Phase 3 EUCTR2017-004605-41-PT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2019 Phase 3 EUCTR2017-004605-41-PL Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2019 Phase 3 EUCTR2017-004605-41-DE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-LT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-HR Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-EE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-CZ Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-BE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Travere Therapeutics, Inc.
2022 Phase 2 EUCTR2021-000621-27-SE France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
2022 Phase 2 EUCTR2021-000621-27-NL France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
2022 Phase 2 EUCTR2021-000621-27-FR France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
2021 Phase 2 EUCTR2021-000621-27-ES France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
- Phase 2 EUCTR2021-000621-27-PL France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
- Phase 2 EUCTR2021-000621-27-DE France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
University of Leicester
2019 Phase 2 EUCTR2018-002012-27-GB United Kingdom
REH-acteoside
Sun Yat-sen University
2016 Phase 2/Phase 3 NCT02662283 China
Risedronate
Osaka University Hospital Department of nephrology
2007 - JPRN-UMIN000002474 Japan
Rituximab
Nan Chen,MD
2020 Phase 4 NCT04525729 China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
2020 Phase 4 ChiCTR2000036468 China
SC0062 high dose
Biocity Biopharmaceutics Co., Ltd.
2023 Phase 2 NCT05687890 China
SC0062 LOW dose
Biocity Biopharmaceutics Co., Ltd.
2023 Phase 2 NCT05687890 China
SC0062 medium dose
Biocity Biopharmaceutics Co., Ltd.
2023 Phase 2 NCT05687890 China
SC0062 strength 10MG
Biocity Biopharmaceutics Co., Ltd.
2025 Phase 3 NCT06819826 China
SCTC21C
Sinocelltech Ltd.
2025 Phase 1/Phase 2 NCT06774664 China
SGB-9768
Suzhou Sanegene Bio Inc.
2025 Phase 2 NCT06786338 China
SHR-2010 injection
Guangdong Hengrui Pharmaceutical Co., Ltd
2023 Phase 2 NCT05847920 China
2022 Phase 1 NCT05398510 China
Sibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
2024 Phase 2 NCT06740526 Canada;United States
Simulect
Centre Hospitalier Universitaire de Saint Etienne
2011 Phase 4 NCT02523768 France
Simvastatin
Fukuoka University Faculty of Medicine
2009 - JPRN-UMIN000002887 Japan
Sirolimus
NEPHROLOGY DEPARTMENT (HOSPITAL UNIVERSITARY OF BELLVITGE)
2005 - EUCTR2005-002610-37-ES Spain
Peking Union Medical College Hospital
2022 Phase 4 ChiCTR2200066031 China
Sirolimus (study drug)+ACE inhibitor + statin
Josep m Cruzado
2006 Phase 2 NCT00396721 Spain
SM101
Baxalta Innovations GmbH
2015 - EUCTR2015-002345-64-CZ Belgium;Canada;Czech Republic;Denmark;Germany;Hong Kong;Sweden;United Kingdom;United States
Baxalta now part of Shire
2015 Phase 2 NCT02605525 -
Solu medrol - 1000 MG/16 ML polvere E solvente PER soluzione iniettabile 1 flacone DI polvere DA 1000 MG+ 1 flacone solvente DA 16 ML
Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
2022 Phase 3 EUCTR2021-006854-29-IT Italy
Sparsentan
Retrophin, Inc.
2018 Phase 3 EUCTR2017-004605-41-ES Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States
TRAVERE THERAPEUTICS, INC
2022 Phase 2 EUCTR2021-000621-27-IT France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
Travere Therapeutics, Inc.
2022 Phase 2 EUCTR2021-000621-27-SE France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
2022 Phase 2 EUCTR2021-000621-27-NL France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
2022 Phase 2 EUCTR2021-000621-27-FR France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
2021 Phase 2 EUCTR2021-000621-27-ES France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
2018 Phase 3 NCT03762850 Australia;Belgium;Croatia;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
- Phase 2 EUCTR2021-000621-27-PL France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
- Phase 2 EUCTR2021-000621-27-DE France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
University of Leicester
2019 Phase 2 EUCTR2018-002012-27-GB United Kingdom
Sparsentan compresse
RETROPHIN, INC
2018 Phase 3 EUCTR2017-004605-41-IT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Sparsentan tablets/OVER-encapsulated sparsentan tablets
Travere Therapeutics Inc.
2019 Phase 3 EUCTR2017-004605-41-PT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-LT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-HR Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-EE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-CZ Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-BE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Sparsentan tablets/OVER-encapsulated spasenten tablets
Travere Therapeutics Inc.
2019 Phase 3 EUCTR2017-004605-41-PL Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Sparsentan tablets/overencapsulated sparsentan tablets
Retrophin, Inc.
2018 Phase 3 EUCTR2017-004605-41-GB Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Travere Therapeutics Inc.
2019 Phase 3 EUCTR2017-004605-41-DE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Steroids plus azathioprine
A. Manzoni Hospital
1998 Phase 4 NCT00755859 Italy;Switzerland
Supportive and immunosuppressive therapy
RWTH Aachen University
2008 Phase 3 NCT00554502 Germany
Supportive therapy
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
Tianjin Hospital
2023 - ChiCTR2500101762 China
Supportive therapy with: ACE-inhibitor / ARB / statin
RWTH Aachen University
2008 Phase 3 NCT00554502 Germany
Tacrolimus
Astellas Pharma Inc
2010 Phase 2 NCT01224028 Korea, Republic of
Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University
2015 - ChiCTR-IPR-15006760 China
Tailored diet
Uppsala University Hospital
2010 - NCT01203007 Norway;Sweden
Tarpeyo 4 MG delayed release oral capsule
Ruijin Hospital
2023 - NCT06589752 China
Telitacicept
Ningxia Medical University General
2024 Phase 0 ChiCTR2400083794 China
RemeGen Co., Ltd.
2023 Phase 3 NCT05799287 China
Second Affiliated Hospital, School of Medicine, Zhejiang University
2023 Phase 2/Phase 3 NCT05596708 China
Shandong Provincial Hospital
2022 Phase 4 ChiCTR2200064790 China
The First Affiliated Hospital of Nanchang University
2024 Phase 4 ChiCTR2400092894 China
The Second Hospital of Shanxi Medical University
2024 - ChiCTR2400083991 China
Xijing hospital
2023 Phase 4 ChiCTR2300076949 China
Telitacicept 160MG
RemeGen Co., Ltd.
2021 Phase 2 NCT04905212 United States
West China Hospital of Sichuan University
2025 - ChiCTR2500096335 China
Telitacicept 240MG
Affiliated Hospital of North Sichuan Medical College
2024 Phase 0 ChiCTR2500098584 China
RemeGen Co., Ltd.
2021 Phase 2 NCT04905212 United States
Ruijin Hospital
2024 - NCT06654596 China
Telmisartan
Chinese General Hospital of PLA
2010 - ChiCTR-TRC-10000776 China
Xiyuan Hospital, China Academy of Chinese Medical Sciences
2021 - ChiCTR2100049833 China
2020 - ChiCTR2000040161 China
2019 - ChiCTR1900022100 China
Tetracycline
Tianjin Hospital
2023 - ChiCTR2500101762 China
THE YI-QI-QING-JIE herbal compound
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
2019 Phase 2/Phase 3 NCT03418779 China
Tofacitinib
Peking Union Medical College Hospital
2022 - ChiCTR2200066045 China
Tripterygium
Hangzhou Hospital of Traditional Chinese Medicine
2012 - ChiCTR-TRC-12002228 China
Nanjing University School of Medicine
2009 - NCT00885547 China
Second Xiangya Hospital of Central South University
2014 Phase 3 NCT02187900 China
Ultomiris
ALEXION PHARMACEUTICALS INCORPORATED
2021 Phase 2 EUCTR2020-001537-13-IT Australia;Belgium;Canada;France;Germany;Italy;Korea, Democratic People's Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Ultomiris 300 MG/30 ML
Dr. Alfons Segarra Medrano
2022 Phase 4 EUCTR2021-005609-28-ES Spain
Vaccino contro IL memingococco DI gruppo B
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Vaccino haemophilus influenzae B coniugato CON tossoidetetanico
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
Vaccino pneumococcico
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Valsartan
ARB therapeutic society of IgA nephropathy
2003 Phase 4 JPRN-C000000380 Japan
Chinese Cardiovascular Association-HX Fund
2023 Phase 4 ChiCTR2300076082 China
Columbia University
2009 Phase 4 NCT01129557 United States
Guangdong General Hospital
2007 Phase 4 NCT00426348 China
Peking Union Medical College Hospital
2016 Phase 4 NCT02765594 China
Shanghai Dong Fang Hospital
2022 - ChiCTR2200063885 China
Shanghai East Hospital (East Hospital Affiliated to Tongji University)
2022 - ChiCTR2200062663 China
Shuguang Hospital affliliated to Shanghai Univesrity of TCM
2016 - ChiCTR-IOR-16010174 China
VIS649
Visterra, Inc.
2020 Phase 2 EUCTR2019-002531-29-GB Australia;Canada;Czech Republic;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Taiwan;Thailand;United Kingdom;United States
2018 Phase 1 NCT03719443 United States
VT-001
Vera Therapeutics, Inc.
2022 Phase 2 EUCTR2020-004892-41-PL Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-GR Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-DE Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-BE Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
Warfarin
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
2001 - JPRN-C000000363 Japan
1998 - JPRN-C000000374 Japan
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
1998 - JPRN-C000000375 Japan
Water
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
2023 Phase 2 ChiCTR2400094993 China
Zigakibart
Novartis Pharmaceuticals
2025 Phase 3 NCT06858319 -
Anthera Pharmaceuticals, Inc
2014 Phase 2;Phase 3 EUCTR2014-001365-26-CZ Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;United Kingdom
Anthera pharmaceuticals, Inc
2015 - EUCTR2014-001365-26-SE Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom
2015 - EUCTR2014-001365-26-IT Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
2015 - EUCTR2014-001365-26-HU Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
2015 Phase 2;Phase 3 EUCTR2014-001365-26-ES Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
2015 Phase 2;Phase 3 EUCTR2014-001365-26-DE Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom
A07ea06
CROWN OY
2012 - EUCTR2012-001923-11-IT Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Abelmoschus manihot
Chen Xiangmei
2014 Phase 4 NCT02231125 China
ACE inhibitor
Yonsei University
2016 Phase 4 NCT02981212 Korea, Republic of
ACE inhibitor or angiotensin receptor antagonist
Peking University First Hospital
2016 - NCT03015974 China
ACE/ARB
Mayo Clinic
2009 Phase 4 NCT00498368 United States
Acei
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
Ningxia Medical University General
2024 Phase 0 ChiCTR2400083794 China
St. Joseph's Hospital and Medical Center, Phoenix
2002 Phase 3 NCT00318474 United States
The First Affiliated Hospital of Zhejiang University
2009 - ChiCTR-TRC-09000338 China
The First Hospital, Peking University
2006 - ChiCTR-TRC-06000004 China
the Second Affiliated Hospital Zhejiang University School of Medicine
2024 Phase 2 ChiCTR2400079954 China
Acei/ARB and corticosteroids
Chulalongkorn University
2012 Phase 4 NCT02571842 Thailand
Acth (acthar) GEL
Mayo Clinic
2015 Phase 3 NCT02282930 United States
Acthar 80 unit injection
Baylor College of Medicine
2015 Phase 4 NCT02382523 United States
Acthib - polvere E solvente PER soluzione iniettabile 1 flaconcino polvere+1 siringa preriempita solvente 0.5 ML
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
ADX-097
Q32 Bio Inc.
2024 Phase 2 NCT06419205 United States
Aliskiren
Chinese University of Hong Kong
2009 Phase 3 NCT00870493 Hong Kong
Columbia University
2009 Phase 4 NCT01129557 United States
Kagawa University
2010 Phase 4 NCT01184599 Japan
The University of Hong Kong
2009 Phase 4 NCT00922311 China
Allopurinol
Sun Yat-sen University
2007 - NCT00793585 China
ALN-CC5
Alnylam Pharmaceuticals Inc
2019 Phase 2 EUCTR2018-002716-27-SE Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2019 Phase 2 EUCTR2018-002716-27-GB Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2019 Phase 2 EUCTR2018-002716-27-ES Australia;Canada;France;Germany;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
ALXN1210
ALEXION PHARMACEUTICALS INCORPORATED
2021 Phase 2 EUCTR2020-001537-13-IT Australia;Belgium;Canada;France;Germany;Italy;Korea, Democratic People's Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Alexion Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-001537-13-SE Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-FR Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-ES Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-DE Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Dr. Alfons Segarra Medrano
2022 Phase 4 EUCTR2021-005609-28-ES Spain
ALXN2050
Alexion Pharmaceuticals, Inc.
2022 Phase 2 EUCTR2021-001426-22-DE Argentina;Australia;Brazil;China;Germany;Israel;Italy;Korea, Republic of;Mexico;Peru;Serbia;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
Ambrisentan
Peking University First Hospital
2024 Phase 3 ChiCTR2400080435 China
Angiotensin
Assistance Publique - Hôpitaux de Paris
2018 Phase 3 NCT03188887 France
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
Angiotensin blockade
The University of Hong Kong
2002 Phase 4 NCT00863252 China
Angiotensin II
Japanese Study Group of Multiple drug therapy for IgAN
2004 - JPRN-C000000341 Japan
ANTI-CD19/bcma CAR NK cells
Jieyang People's Hospital
2025 Early Phase 1 NCT06926985 China
APL-2
Apellis Pharmaceuticals, Inc.
2018 Phase 2 NCT03453619 United States
ARB
ARB therapeutic society of IgA nephropathy
2003 Phase 4 JPRN-C000000380 Japan
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
Ningxia Medical University General
2024 Phase 0 ChiCTR2400083794 China
The First Affiliated Hospital of Zhejiang University
2009 - ChiCTR-TRC-09000338 China
The First Hospital, Peking University
2006 - ChiCTR-TRC-06000004 China
Yonsei University
2016 Phase 4 NCT02981212 Korea, Republic of
the Second Affiliated Hospital Zhejiang University School of Medicine
2024 Phase 2 ChiCTR2400079954 China
ARO-C3
Arrowhead Pharmaceuticals
2022 Phase 1/Phase 2 NCT05083364 Australia;Georgia;Germany;Korea, Republic of;New Zealand;Spain;Thailand;United Kingdom
ARO-CFB
Arrowhead Pharmaceuticals
2024 Phase 1/Phase 2 NCT06209177 New Zealand
Artesunate
Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine
2020 Phase 0 ChiCTR2000038104 China
AT-1501
Eledon Pharmaceuticals
2022 Phase 2 NCT05125068 Australia;Croatia;Malaysia;New Zealand;Philippines;Poland;Spain;Sri Lanka;Thailand;United Kingdom
Eledon Pharmaceuticals, Inc
2022 Phase 2 EUCTR2021-004795-34-PL Australia;China;Croatia;Malaysia;New Zealand;Philippines;Poland;Spain;Sri Lanka;Thailand
2022 Phase 2 EUCTR2021-004795-34-ES Australia;China;Croatia;Malaysia;New Zealand;Philippines;Poland;Spain;Sri Lanka;Thailand
Atacicept
Israni Rubeen
2024 Phase 3 JPRN-jRCT2031230629 Argentina;Australia;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hong Kong;India;Ireland;Italy;Japan;Malaysia;Philippines;Poland;Portugal;Singapore;South Korea;Spain;Sri Lanka;Taiwan;Thailand;Turkey;United Kingdom;United States
Merck KGaA
2017 Phase 2 EUCTR2016-002262-31-GB Belgium;Czech Republic;France;Israel;Italy;Japan;Korea, Republic of;Singapore;Spain;Taiwan;United Kingdom;United States
Vera Therapeutics, Inc.
2023 Phase 3 NCT04716231 Australia;Belgium;Canada;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2022 Phase 2 EUCTR2020-004892-41-PL Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-GR Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-DE Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-BE Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
Atacicept 150 MG
Merck Biopharma Co., Ltd.
2017 Phase 2 JPRN-jRCT2080223899 Europe;Japan
Vera Therapeutics, Inc.
2024 Phase 2 NCT06674577 United States
Atacicept 25 MG
EMD Serono Research & Development Institute, Inc.
2017 Phase 2 NCT02808429 Germany;Japan;United Kingdom;United States
Merck Biopharma Co., Ltd.
2017 Phase 2 JPRN-jRCT2080223899 Europe;Japan
Atacicept 75 MG
EMD Serono Research & Development Institute, Inc.
2017 Phase 2 NCT02808429 Germany;Japan;United Kingdom;United States
Merck Biopharma Co., Ltd.
2017 Phase 2 JPRN-jRCT2080223899 Europe;Japan
ATG-F
Centre Hospitalier Universitaire de Saint Etienne
2011 Phase 4 NCT02523768 France
Atrasentan
CHINOOK THERAPEUTICS, U.S., Inc
2021 Phase 3 EUCTR2020-003084-26-IT Argentina;Australia;Brazil;Canada;China;Czech Republic;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Chinook Therapeutics U.S., Inc.
2022 Phase 3 EUCTR2020-003084-26-PT Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2022 Phase 3 EUCTR2020-003084-26-IE Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Taiwan;United States
2021 Phase 3 EUCTR2020-003084-26-PL Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2021 Phase 3 EUCTR2020-003084-26-FR Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Taiwan;United Kingdom;United States
2021 Phase 3 EUCTR2020-003084-26-DE Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2021 Phase 3 EUCTR2020-003084-26-CZ Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;Czechia;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Chinook Therapeutics, Inc.
2020 Phase 3 NCT04573478 Argentina;Australia;Brazil;Canada;China;Colombia;Czechia;France;Germany;Hong Kong;India;Ireland;Italy;Japan;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Fukui Tomoaki
2021 Phase 3 JPRN-jRCT2071210028 Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Hong Kong;India;Italy;Japan;New Zealand;Poland;South Korea;Spain;Taiwan;United Kingdom;United States
Novartis Pharmaceuticals
2023 Phase 2 NCT06841094 Australia;Brazil;Korea, Republic of;Malaysia;Spain;United States
2023 Phase 2 NCT05834738 Australia;Brazil;Korea, Republic of;Malaysia;Spain;United States
2021 Phase 2 NCT04573920 Australia;Italy;Korea, Republic of;Spain;United Kingdom;United States
Avacopan
Mayo Clinic
2025 Phase 2 NCT06676579 United States
AVB-S6-500
Aravive, Inc.
2019 Phase 2 NCT04042623 United States
Azathioprine
A. Manzoni Hospital
1999 Phase 3 NCT01392833 -
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
Azilsartan
Chinese Cardiovascular Association-HX Fund
2023 Phase 4 ChiCTR2300076082 China
Bardoxolone methyl capsules
Reata, a wholly owned subsidiary of Biogen
2017 Phase 2 NCT03366337 United States
BCX9930 hydrochloride
BIOCRYST PHARMACEUTICALS INC.
2021 Phase 2 EUCTR2020-005855-19-IT France;Germany;Hungary;Italy;Spain;United Kingdom
BioCryst Pharmaceuticals Inc
2022 Phase 2 EUCTR2020-005855-19-HU France;Germany;Hungary;Italy;Romania;Spain;United Kingdom
2021 Phase 2 EUCTR2020-005855-19-ES France;Germany;Hungary;Italy;Spain;United Kingdom
Belimumab
University of Leicester
2019 Phase 2 EUCTR2017-004366-10-GB United Kingdom
Benlysta
University of Leicester
2019 Phase 2 EUCTR2017-004366-10-GB United Kingdom
Bexsero - sospensione iniettabile - USO intramuscolare - siringa preriempita (vetro) - 0.5ML - 1 siringa preriempita CON AGO
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
BIO-kult advanced
University of Leicester
2023 - NCT06767592 United Kingdom
BION-1301
Chinook Therapeutics, Inc.
2023 Phase 3 NCT05852938 Argentina;Australia;Belgium;Brazil;Canada;China;Croatia;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Spain;Taiwan;Turkey;United Kingdom;United States
BION-1301 multiple doses
Novartis Pharmaceuticals
2019 Phase 1/Phase 2 NCT03945318 Korea, Republic of;United Kingdom;United States
BION-1301 single dose
Novartis Pharmaceuticals
2019 Phase 1/Phase 2 NCT03945318 Korea, Republic of;United Kingdom;United States
Blisibimod
Anthera Pharmaceuticals
2014 Phase 3 NCT02052219 -
2013 Phase 2/Phase 3 NCT02062684 Canada;Czech Republic;Czechia;Germany;Hong Kong;Italy;Korea, Republic of;Malaysia;Philippines;Russian Federation;Singapore;Spain;Taiwan;Thailand;United Kingdom
Blisibimod injection
Anthera Pharmaceuticals, Inc
2014 Phase 2;Phase 3 EUCTR2014-001365-26-CZ Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;United Kingdom
Anthera pharmaceuticals, Inc
2015 - EUCTR2014-001365-26-SE Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom
2015 - EUCTR2014-001365-26-IT Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
2015 - EUCTR2014-001365-26-HU Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
2015 Phase 2;Phase 3 EUCTR2014-001365-26-ES Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom
2015 Phase 2;Phase 3 EUCTR2014-001365-26-DE Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom
Blood sample
Centre Hospitalier Universitaire de Saint Etienne
2012 - NCT02526966 France
BNJ441
Alexion Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-001537-13-SE Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-ES Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-DE Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Bortezomib
Ruijin Hospital
2022 - NCT05383547 China
The Rogosin Institute
2010 Phase 4 NCT01103778 United States
Budesonide
CALLIDITAS THERAPEUTICS AB
2020 Phase 3 EUCTR2020-003308-14-IT Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-IT Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom
CROWN OY
2012 - EUCTR2012-001923-11-IT Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Calliditas Therapeutics AB
2021 Phase 3 EUCTR2020-003308-14-FI Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-003308-14-BE Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-SE Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-PL Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-GR Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-GB Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-FR Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-CZ Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-SE Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-PL Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-GB Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-FI Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-ES Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-CZ Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-BE Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Pharmalink AB
2013 - EUCTR2012-001923-11-ES Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-SE Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-NL Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-GB Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-FI Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-DK Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-DE Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-CZ Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-BE Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2005 Phase 2 NCT00767221 Sweden
The First Affiliated Hospital of Air Force Medical University
2025 - ChiCTR2500103064 China
The First Affiliated Hospital,Sun Yat-sen University
2025 - ChiCTR2500097089 China
C09
RETROPHIN, INC
2018 Phase 3 EUCTR2017-004605-41-IT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Calcitriol
Chinese University of Hong Kong
2006 Phase 4 NCT00319761 Hong Kong
Osaka University Hospital Department of nephrology
2007 - JPRN-UMIN000002474 Japan
Yonsei University
2011 - NCT01237028 Korea, Republic of
CCX168
Amgen
2015 Phase 2 NCT02384317 Sweden;United States
ChemoCentryx, Inc.
2015 Phase 2 EUCTR2014-003402-33-SE Belgium;Sweden;United States
2015 Phase 2 EUCTR2014-003402-33-BE Belgium;Sweden;United States
Cemdisiran
Alnylam Pharmaceuticals
2019 Phase 2 NCT03841448 Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Alnylam Pharmaceuticals Inc
2019 Phase 2 EUCTR2018-002716-27-SE Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2019 Phase 2 EUCTR2018-002716-27-GB Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2019 Phase 2 EUCTR2018-002716-27-ES Australia;Canada;France;Germany;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Chinese herb prescription granule plus prednisone
Shanghai University of Traditional Chinese Medicine
2010 - NCT01879514 China
Cilazapril
The First Hospital, Peking University
2006 - ChiCTR-TRC-06000004 China
CM313
Keymed Biosciences Co.Ltd
2025 Phase 2 NCT06830395 -
CM338
Keymed Biosciences Co.Ltd
2023 Phase 2 NCT05775042 China
Continue their usual therapy
Sun Yat-sen University
2007 - NCT00793585 China
Corticosteroid
Peking University First Hospital
2016 - NCT03015974 China
Yonsei University
2016 Phase 4 NCT02981212 Korea, Republic of
Corticotherapy
Assistance Publique - Hôpitaux de Paris
2018 Phase 3 NCT03188887 France
Creatinine
Affiliated Hospital of North Sichuan Medical College
2024 Phase 0 ChiCTR2500098584 China
Cyclophosphamid
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
Cyclophosphamide
Peking University First Hospital
2016 - NCT03015974 China
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
The First Affiliated Hospital of Air Force Medical University
2025 - ChiCTR2500103064 China
the First Affiliated Hospital of Zhengzhou University
2024 Phase 4 ChiCTR2400083736 China
Dapagliflozin
Daping Hospital, Army Medical University
2023 Phase 4 ChiCTR2300067263 China
Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
2022 Phase 3 EUCTR2021-006854-29-IT Italy
Shenzhen People's Hospital
2024 Phase 1 ChiCTR2400088054 China
Travere Therapeutics, Inc.
2018 Phase 3 NCT03762850 Australia;Belgium;Croatia;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Decortin H
Universitätsklinikum Ulm
2008 - EUCTR2007-000443-99-DE Germany
Dihuang
Zhejiang Provincal Hospital of Traditional Chinese Medicine
2021 Phase 0 ChiCTR2100042331 China
Dipyridamole
Peking University First Hospital
2016 - NCT03015974 China
2013 - ChiCTR-TRC-13003038 China
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
2001 - JPRN-C000000363 Japan
1998 - JPRN-C000000374 Japan
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
1998 - JPRN-C000000375 Japan
Enalapril
ARB therapeutic society of IgA nephropathy
2003 Phase 4 JPRN-C000000380 Japan
National Center for Research Resources (NCRR)
2000 - NCT00006137 -
Enalapril valsartan methylprednisone
Hospital Britanico
1996 Phase 4 NCT00367562 Argentina
Fecal microbiota transplantation
Air Force Military Medical University, China
2017 Phase 2 NCT03633864 China
Felzartamab
Biogen
2025 Phase 3 NCT06935357 United States
HI-Bio, A Biogen Company
2021 Phase 2 NCT05065970 Australia;Belgium;Bulgaria;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
Human Immunology Biosciences, Inc
2021 Phase 2 EUCTR2020-005054-19-DE Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-CZ Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-BG Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
MorphoSys AG
2021 Phase 2 EUCTR2020-005054-19-ES Australia;Belgium;Bulgaria;Canada;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-BE Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
Finerenone
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2022 - NCT06460987 China
Zhejiang University
2024 Phase 3 NCT06580288 -
FOS
St. Joseph's Hospital and Medical Center, Phoenix
2002 Phase 3 NCT00318474 United States
Fostamatinib 100 MG
Rigel Pharmaceuticals
2014 Phase 2 NCT02112838 Austria;Germany;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib 100 MG tablet
Rigel Pharmaceuticals Inc
2014 Phase 2 EUCTR2014-000331-16-GB Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
2014 Phase 2 EUCTR2014-000331-16-AT Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib 150 MG
Rigel Pharmaceuticals
2014 Phase 2 NCT02112838 Austria;Germany;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib 150 MG tablet
Rigel Pharmaceuticals Inc
2014 Phase 2 EUCTR2014-000331-16-GB Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
2014 Phase 2 EUCTR2014-000331-16-AT Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib disodium
Rigel Pharmaceuticals Inc
2014 Phase 2 EUCTR2014-000331-16-GB Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
2014 Phase 2 EUCTR2014-000331-16-AT Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Fostamatinib disodium tablet 100 MG
Rigel Pharmaceuticals
2015 Phase 2 NCT02433236 -
Fostamatinib disodium tablet 150 MG
Rigel Pharmaceuticals
2015 Phase 2 NCT02433236 -
Gastrus
Uppsala University Hospital
2013 - NCT01781312 Sweden
Glucocorticoid
Ruijin Hospital
2024 - NCT06654596 China
West China Hospital of Sichuan University
2025 - ChiCTR2500096335 China
the First Affiliated Hospital of Zhengzhou University
2024 Phase 4 ChiCTR2400083736 China
Glucose
Assistance Publique - Hôpitaux de Paris
2018 Phase 3 NCT03188887 France
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
GSK1550188
University of Leicester
2019 Phase 2 EUCTR2017-004366-10-GB United Kingdom
GUT-directed budesonide and SOC
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
Haemophilus influenzae
NOVARTIS PHARMA AG
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Henagliflozin
Peking University First Hospital
2024 Phase 3 ChiCTR2400080435 China
Hiberix - polvere E solvente PER soluzione iniettabile PER USO intramuscolare 1 flaconcino DI polvere + 1 siringa preriempita DI solvente DA 0.5 ML
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
High DOSE-VIS649
Visterra, Inc.
2020 Phase 2 NCT04287985 Australia;Canada;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sri Lanka;Taiwan;Thailand;United Kingdom;United States
HR19042 capsule
Jiangsu HengRui Medicine Co., Ltd.
2023 Phase 1 NCT06922305 China
2021 Phase 1 NCT04887532 China
HR19042 capsules
Jiangsu HengRui Medicine Co., Ltd.
2021 Phase 2 NCT05016323 China
HRS-5965
Chengdu Suncadia Medicine Co., Ltd.
2023 Phase 2 NCT06137768 China
HRS-5965 capsules
Chengdu Suncadia Medicine Co., Ltd.
2024 Phase 1 NCT06490991 China
HRS-5965 tablets
Chengdu Suncadia Medicine Co., Ltd.
2024 Phase 1 NCT06490991 China
HS-10390
Hansoh BioMedical R&D Company
2024 Phase 2 NCT06635772 China
HS-10390 tablet
Hansoh BioMedical R&D Company
2023 Phase 1 NCT05942625 China
HSK39297 100mgbid
Haisco Pharmaceutical Group Co., Ltd.
2024 Phase 2 NCT06670352 China
HSK39297 200mgqd
Haisco Pharmaceutical Group Co., Ltd.
2024 Phase 2 NCT06670352 China
HSK39297 50mgbid
Haisco Pharmaceutical Group Co., Ltd.
2024 Phase 2 NCT06670352 China
Human soluble recombinant FC-gamma receptor IIB
Baxalta Innovations GmbH
2015 - EUCTR2015-002345-64-CZ Belgium;Canada;Czech Republic;Denmark;Germany;Hong Kong;Sweden;United Kingdom;United States
Hydroxychloroquine
Department of Pharmacy, Drum Tower Hospital Affiliated to Nanjing University Medical School
2021 Phase 1 ChiCTR2100052910 China
Peking University First Hospital
2021 Phase 0 ChiCTR2100045306 China
Shanxi Medical University Second Hospital
2024 Phase 4 ChiCTR2400093530 China
Hydroxychloroquine and SOC
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
Hydroxychloroquine oral tablet
Centre Hospitalier Universitaire de Saint Etienne
2025 Phase 2 NCT06350630 France
Hydroxychloroquine sulfate
LLiu
2015 Phase 4 NCT02351752 China
Peking Union Medical College Hospital
2016 Phase 4 NCT02765594 China
Peking University First Hospital
2016 Phase 2 NCT02942381 China
Immune suppressant
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2022 - NCT06460987 China
Immunosuppressants
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
2019 Phase 2/Phase 3 NCT03418779 China
The Second Hospital of Shanxi Medical University
2024 - ChiCTR2400083991 China
Tianjin Hospital
2023 - ChiCTR2500101762 China
Immunosuppressive treatment
Yonsei University
2019 Phase 4 NCT03468972 Korea, Republic of
Inhibace/cozaar
Peking University
2006 - NCT00378443 -
Intensive supportive care
Yonsei University
2019 Phase 4 NCT03468972 Korea, Republic of
Intervention FOR incipient patients AT LOW risk OF disease progression
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2020 - NCT04438603 China
Intervention FOR patients AT high risk OF disease progression
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2020 - NCT04438603 China
Intravenous rituximab
Chulalongkorn University
2012 Phase 4 NCT02571842 Thailand
Mayo Clinic
2009 Phase 4 NCT00498368 United States
Ionis-FB-LRX
Ionis Pharmaceuticals, Inc.
2019 Phase 2 NCT04014335 Australia;Canada;New Zealand;Singapore
Iptacopan
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
Novartis Pharma AG
2023 Phase 3 EUCTR2020-002200-40-FR Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-CZ Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-FR Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
2021 Phase 3 EUCTR2020-001049-38-CZ Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2020 Phase 3 EUCTR2020-001049-38-HU Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
2020 Phase 3 EUCTR2020-001049-38-FI Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2019 Phase 2 EUCTR2017-000891-27-CZ Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-SE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-NL Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-FI Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-DK Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-DE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2017 Phase 2 EUCTR2017-000891-27-GB Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Pharmaceuticals
2025 Phase 2 NCT06797518 -
Iptacopan hydrochloride
Novartis Pharma AG
2022 Phase 3 EUCTR2020-002200-40-DK Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2020-001049-38-SK Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2020-001049-38-SI Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-NO Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-NL Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-DE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-BE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-SE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-NO Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-NL Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-DK Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-BE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2020 Phase 3 EUCTR2020-001049-38-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
Irbesartan
AZIENDA OSPEDALIERA PROVINCIALE DI LECCO
2005 - EUCTR2005-003885-40-IT Italy
Hansoh BioMedical R&D Company
2024 Phase 2 NCT06635772 China
Sun Yat-sen University
2007 Phase 3 NCT00657059 China
Travere Therapeutics, Inc.
2018 Phase 3 NCT03762850 Australia;Belgium;Croatia;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Yueyang Integrated Traditional Chinese and Western Medicine Hospital, Affiliated with Shanghai University of Traditional Chinese Medicine
2024 Phase 1 ChiCTR2400082620 China
Irbesartan tablets (approved IN THE USA. reference listed drug avapro) NDC # 43547-0374-03
Retrophin, Inc.
2018 Phase 3 EUCTR2017-004605-41-GB Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-ES Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States
KP104
Kira Pharmacenticals (US), LLC.
2025 Phase 2 NCT05517980 -
Leflunomide
Chinese General Hospital of PLA
2010 - ChiCTR-TRC-10000776 China
The First Affiliated Hospital of Chengdu Medical College
2018 - ChiCTR1800019606 China
Leflunomide 20 MG+prednisone 0.5MG/KG/D
Shenzhen Second People's Hospital
2019 Phase 4 NCT04020328 China
Lisinopril
Japanese Study group of Kidney Disease in Children
2005 - JPRN-C000000006 Japan
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
1998 - JPRN-C000000373 Japan
LNP023
Novartis Pharma AG
2023 Phase 3 EUCTR2020-002200-40-FR Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2020-002200-40-DK Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2020-001049-38-SK Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2020-001049-38-SI Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-NO Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-NL Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-DE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-CZ Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-002200-40-BE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-SE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-NO Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-NL Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-FR Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
2021 Phase 3 EUCTR2020-001049-38-DK Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-CZ Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-BE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2020 Phase 3 EUCTR2020-001049-38-HU Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
2020 Phase 3 EUCTR2020-001049-38-FI Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2020 Phase 3 EUCTR2020-001049-38-DE Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2019 Phase 2 EUCTR2017-000891-27-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2019 Phase 2 EUCTR2017-000891-27-HU Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2019 Phase 2 EUCTR2017-000891-27-FR Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2019 Phase 2 EUCTR2017-000891-27-CZ Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-SE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-NL Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-FI Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-DK Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-DE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 EUCTR2017-000891-27-BE Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2017 Phase 2 EUCTR2017-000891-27-GB Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Pharmaceuticals
2021 Phase 3 NCT04578834 Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Puerto Rico;Russian Federation;Singapore;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
2021 Phase 3 NCT04557462 Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
2018 Phase 2 NCT03373461 Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Norway;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
LNP023 hydrochlori
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
Losartan
Chen Xiangmei
2014 Phase 4 NCT02231125 China
Fukuoka University Faculty of Medicine
2009 - JPRN-UMIN000002887 Japan
Hu Qianqian
2018 Phase 0 ChiCTR2200058382 China
Japanese Study group of Kidney Disease in Children
2005 - JPRN-C000000006 Japan
Jiujiang Hospital of Traditional Chinese Medicine
2023 Phase 0 ChiCTR2200066983 China
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
2023 Phase 2 ChiCTR2400094993 China
The First Hospital, Peking University
2006 - ChiCTR-TRC-06000004 China
The Third Xiangya Hospital of Central South University
2018 Phase 4 study ChiCTR-IIR-17013487 China
LOW antigen content diet
Uppsala University Hospital
2010 - NCT01203007 Norway;Sweden
LOW DOSE-VIS649
Visterra, Inc.
2020 Phase 2 NCT04287985 Australia;Canada;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sri Lanka;Taiwan;Thailand;United Kingdom;United States
MASP-2 antibody, OMS00620646, OMS620646
Omeros Corporation
2021 Phase 3 EUCTR2018-000075-33-GR Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-SK Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-SE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-PL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-LT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-BG Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-BE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
Medium DOSE-VIS649
Visterra, Inc.
2020 Phase 2 NCT04287985 Australia;Canada;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sri Lanka;Taiwan;Thailand;United Kingdom;United States
Menatetrenone
Osaka University Hospital Department of nephrology
2007 - JPRN-UMIN000002474 Japan
Menveo - polv.E soluz.PER soluz. iniett.-USO intramuscolare-comp. coniug.liofilizz.mena:flac.(vetro) comp. goniug.liqui.mencwy:flac.(vetro)-1 flac+1flac
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Metformin
West China Hospital of Sichuan University
2025 - ChiCTR2500096335 China
Methylprednisolon
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
Methylprednisolone
A. Manzoni Hospital
1999 Phase 3 NCT01392833 -
Mayo Clinic
2025 Phase 2 NCT06676579 United States
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
Sixth Affiliated Hospital, Sun Yat-sen University
2021 Phase 3 NCT04833374 China
Sun Yat-sen University
2014 Phase 2 NCT02160132 China
2007 Phase 3 NCT00657059 China
The George Institute
2012 - NCT01560052 Australia;Canada;China;Hong Kong;India;Malaysia
Zhongshan Hospital of Fudan University
2008 - ChiCTR-TRC-09000607 China
Methylprednisolone mylan GéNérique
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2017 Phase 3 EUCTR2016-004507-31-FR France
Methylprednisolone pulse
Peking University First Hospital
2016 Phase 2/Phase 3 NCT02647255 China
West Japan Study Group for Therapy of IgA Nephropathy
2006 - JPRN-UMIN000000593 Japan
the First Affiliated Hospital of Zhengzhou University
2024 Phase 4 ChiCTR2400083736 China
Methylprednisolone succinate
Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
2022 Phase 3 EUCTR2021-006854-29-IT Italy
Metilprednisolone sodio succinato
Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
2022 Phase 3 EUCTR2021-006854-29-IT Italy
Mezagitamab
Nishizawa Atsushi
2022 Phase 1 JPRN-jRCT2011220009 Australia;Belgium;China;Hungary;Italy;Japan;Serbia;Singapore;South Korea;Spain;Taiwan;UK;USA
Takeda
2025 Phase 3 NCT06963827 -
2022 Phase 1 NCT05174221 Australia;Belgium;China;Hungary;Italy;Japan;Korea, Republic of;Serbia;Singapore;Spain;Taiwan;United Kingdom;United States
Mizoribine
Japanese Study Group of Multiple drug therapy for IgAN
2004 - JPRN-C000000341 Japan
Nanjing general hospital of Nanjing military command
2011 - ChiCTR-ONC-10001124 China
Peking University First Hospital
2013 - ChiCTR-TRC-13003038 China
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
2001 - JPRN-C000000363 Japan
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
1998 - JPRN-C000000375 Japan
West Japan Study Group for Therapy of IgA Nephropathy
2006 - JPRN-UMIN000000593 Japan
MMF
Second Xiangya Hospital of Central South University
2014 Phase 3 NCT02187900 China
St. Joseph's Hospital and Medical Center, Phoenix
2002 Phase 3 NCT00318474 United States
Sun Yat-sen University
2007 Phase 3 NCT00657059 China
Zhongshan Hospital of Fudan University
2008 - ChiCTR-TRC-09000607 China
MOR03087
Human Immunology Biosciences, Inc
2021 Phase 2 EUCTR2020-005054-19-DE Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-CZ Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-BG Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
MorphoSys AG
2021 Phase 2 EUCTR2020-005054-19-ES Australia;Belgium;Bulgaria;Canada;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-BE Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
MOR202
Human Immunology Biosciences, Inc
2021 Phase 2 EUCTR2020-005054-19-DE Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-CZ Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-BG Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
MorphoSys AG
2021 Phase 2 EUCTR2020-005054-19-ES Australia;Belgium;Bulgaria;Canada;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 2 EUCTR2020-005054-19-BE Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States
MY008211A tablets
Wuhan Createrna Science and Technology Co., Ltd
2024 Phase 2 NCT06687174 China
Mycophenolat-natrium
Universitätsklinikum Ulm
2008 - EUCTR2007-000443-99-DE Germany
Mycophenolate mofetil
Nanjing University School of Medicine
2003 - NCT00301600 China
Peking University First Hospital
2016 - NCT03015974 China
Second Xiangya Hospital of Central South University
2014 Phase 3 NCT02187900 China
St. Joseph's Hospital and Medical Center, Phoenix
2002 Phase 3 NCT00318474 United States
Sun Yat-sen University
2007 Phase 3 NCT00657059 China
The First Affiliated Hospital of Air Force Medical University
2025 - ChiCTR2500103064 China
The University of Hong Kong
2002 Phase 4 NCT00863252 China
Yonsei University
2016 Phase 4 NCT02981212 Korea, Republic of
the First Affiliated Hospital of Zhengzhou University
2024 Phase 4 ChiCTR2400083736 China
Mycophenolate mofetil (MMF) and SOC
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
Mycophenolate mofetil plus lower dose OF prednisone
Zhi-Hong Liu, M.D.
2010 - NCT01269021 China
Mycophenolate sodium
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
2022 Phase 4 ChiCTR2200060990 China
UHB NHS Foundation Trust
2010 Phase 2 EUCTR2009-016003-26-GB United Kingdom
Mycophenolic acid
UHB NHS Foundation Trust
2010 Phase 2 EUCTR2009-016003-26-GB United Kingdom
Mycophenolic sodium
UHB NHS Foundation Trust
2010 Phase 2 EUCTR2009-016003-26-GB United Kingdom
Myfortic
Universitätsklinikum Ulm
2008 - EUCTR2007-000443-99-DE Germany
Myfortic 180MG tablets
UHB NHS Foundation Trust
2010 Phase 2 EUCTR2009-016003-26-GB United Kingdom
Myfortic 360MG tablets
UHB NHS Foundation Trust
2010 Phase 2 EUCTR2009-016003-26-GB United Kingdom
Narsoplimab
Omeros Corporation
2021 Phase 3 EUCTR2018-000075-33-GR Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-SK Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-SE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-PL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-LT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-BG Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-BE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2016 Phase 2 NCT02682407 Hong Kong;United States
Nefecon
CALLIDITAS THERAPEUTICS AB
2020 Phase 3 EUCTR2020-003308-14-IT Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-IT Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom
CROWN OY
2012 - EUCTR2012-001923-11-IT Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Calliditas Therapeutics AB
2021 Phase 3 EUCTR2020-003308-14-FI Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-003308-14-BE Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-SE Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-PL Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-GR Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-GB Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-FR Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2020-003308-14-CZ Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 NCT03643965 Argentina;Australia;Belarus;Belgium;Canada;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-SE Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-PL Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-GB Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-FI Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-ES Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-CZ Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2017-004902-16-BE Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States
Everest Medicines (Singapore) Pte. Ltd.
2022 Phase 3 NCT05534919 China
Pharmalink AB
2013 - EUCTR2012-001923-11-ES Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 NCT01738035 Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-SE Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-NL Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-GB Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 - EUCTR2012-001923-11-FI Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-DK Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-DE Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-CZ Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
2012 Phase 2 EUCTR2012-001923-11-BE Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom
Nefecon 16MG daily
Calliditas Therapeutics AB
2020 Phase 3 NCT04541043 Argentina;Australia;Belarus;Belgium;Canada;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Turkey;United Kingdom;United States
NM8074
NovelMed Therapeutics
2025 Phase 2 NCT06454110 -
NON-steroidal mineralocorticoid receptor antagonist and SOC
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
NTQ5082 capsules 100 MG
Nanjing Chia-tai Tianqing Pharmaceutical
2025 Phase 2 NCT06982040 -
NTQ5082 capsules 200 MG
Nanjing Chia-tai Tianqing Pharmaceutical
2025 Phase 2 NCT06982040 -
NTQ5082 capsules 300 MG
Nanjing Chia-tai Tianqing Pharmaceutical
2025 Phase 2 NCT06982040 -
Omega-3 fatty acid ethylester90
Kuhnil Pharmaceutical Co., Ltd.
2007 Phase 3 NCT00549692 Korea, Republic of
Omega-3 fatty acid fish OIL supplement
Mayo Clinic
2009 Phase 4 NCT00498368 United States
OMS721
OMEROS CORPORATION
2019 Phase 3 EUCTR2018-000075-33-IT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Korea, Democratic People's Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States
Omeros Corporation
2021 Phase 3 EUCTR2018-000075-33-GR Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2019 Phase 3 EUCTR2018-000075-33-GB Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States
2019 Phase 3 EUCTR2018-000075-33-DE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 NCT03608033 Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-SK Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-SE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-PL Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-LT Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-HU Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-ES Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-CZ Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-BG Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-BE Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Germany;Greece;Hungary;India;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 3 EUCTR2018-000075-33-AT Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Hungary;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;United States
2016 Phase 2 NCT02682407 Hong Kong;United States
OPL-CCL2-LPM
Osprey Pharmaceuticals USA, Inc.
2009 Phase 1 NCT00856674 Canada
Optimized supportive care
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
2019 Phase 2/Phase 3 NCT03418779 China
Oral prednisolone and SOC
Christian Medical College, Vellore, India
2024 Phase 4 NCT06676384 India
OVER-encapsulated 150 MG irbesartan tablets
Retrophin, Inc.
2018 Phase 3 EUCTR2017-004605-41-ES Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States
OVER-encapsulated irbesartan tablets
RETROPHIN, INC
2018 Phase 3 EUCTR2017-004605-41-IT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Travere Therapeutics Inc.
2019 Phase 3 EUCTR2017-004605-41-PT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2019 Phase 3 EUCTR2017-004605-41-PL Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2019 Phase 3 EUCTR2017-004605-41-DE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-LT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-HR Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-EE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-CZ Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-BE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Paricalcitol
Chinese University of Hong Kong
2008 Phase 3 NCT00599963 China;Hong Kong
Pneumovax – soluzione iniettabile IN siringa preriempita DA 0,5 ML
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Potassium
Hu Qianqian
2018 Phase 0 ChiCTR2200058382 China
Jiujiang Hospital of Traditional Chinese Medicine
2023 Phase 0 ChiCTR2200066983 China
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
2023 Phase 2 ChiCTR2400094993 China
The Third Xiangya Hospital of Central South University
2018 Phase 4 study ChiCTR-IIR-17013487 China
Yueyang Integrated Traditional Chinese and Western Medicine Hospital, Affiliated with Shanghai University of Traditional Chinese Medicine
2024 Phase 1 ChiCTR2400082620 China
Prednisolon
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
Universitätsklinikum Ulm
2008 - EUCTR2007-000443-99-DE Germany
Prednisolone
Japanese Study Group of Multiple drug therapy for IgAN
2004 - JPRN-C000000341 Japan
Juntendo University
2018 - JPRN-UMIN000032031 Japan
Mayo Clinic
2025 Phase 2 NCT06676579 United States
Nephrology Department, Hangzhou Hospital of Traditional Chinese Medicine, Zhejiang Province
2019 Phase 0 ChiCTR1900026883 China
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
Sun Yat-sen University
2016 Phase 2/Phase 3 NCT02662283 China
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
2001 - JPRN-C000000363 Japan
1998 - JPRN-C000000374 Japan
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
1998 - JPRN-C000000375 Japan
UHB NHS Foundation Trust
2010 Phase 2 EUCTR2009-016003-26-GB United Kingdom
West Japan Study Group for Therapy of IgA Nephropathy
2006 - JPRN-UMIN000000593 Japan
Prednisolone plus cyclophosphamide
Air Force Military Medical University, China
2024 Phase 3 NCT05510323 China
Prednisone
A. Manzoni Hospital
1999 Phase 3 NCT01392833 -
Department of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine
2010 - ChiCTR-TRC-13003702 China
Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
2022 Phase 3 EUCTR2021-006854-29-IT Italy
Mayo Clinic
2025 Phase 2 NCT06676579 United States
Peking University
2006 - NCT00378443 -
Shanghai University of Traditional Chinese Medicine
2016 - NCT02712697 China
Sun Yat-sen University
2007 Phase 3 NCT00657059 China
The First Affiliated Hospital of Xi'an Jiaotong University Medical College
2010 - ChiCTR-TRC-10000824 China
The First Affiliated Hospital of Zhejiang University
2009 - ChiCTR-TRC-09000338 China
The First Hospital, Peking University
2006 - ChiCTR-TRC-06000004 China
Xijing hospital
2023 Phase 4 ChiCTR2300076949 China
Yancheng Third People's Hospital
2011 - ChiCTR-OPN-16010028 -
the First Affiliated Hospital of Zhengzhou University
2024 Phase 4 ChiCTR2400083736 China
Prednisone 5 MG
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2017 Phase 3 EUCTR2016-004507-31-FR France
Prednisone alone
Guangdong General Hospital
2016 Phase 4 NCT03218852 China
2012 Phase 4 NCT01758120 China
Prednisone and cyclophosphamide
Guangdong General Hospital
2016 Phase 4 NCT03218852 China
Prednisone arrow 20MG
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2017 Phase 3 EUCTR2016-004507-31-FR France
Prednisone arrow 5 MG
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2017 Phase 3 EUCTR2016-004507-31-FR France
Prednisone IN full dose
Zhi-Hong Liu, M.D.
2010 - NCT01269021 China
Prednisone or prednisolone
Nanjing University School of Medicine
2011 - NCT01451710 China
Prednisone plus cyclophosphamide
Guangdong General Hospital
2012 Phase 4 NCT01758120 China
Probiotics combined with enteric-coated budesonide capsule
Gang Xu
2024 Phase 4 NCT06528015 China
Probucol
Guangdong General Hospital
2007 Phase 4 NCT00426348 China
Proline
the Second Affiliated Hospital Zhejiang University School of Medicine
2024 Phase 2 ChiCTR2400079954 China
Protectis
Uppsala University Hospital
2013 - NCT01781312 Sweden
R935788
Rigel Pharmaceuticals Inc
2014 Phase 2 EUCTR2014-000331-16-GB Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
2014 Phase 2 EUCTR2014-000331-16-AT Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States
Ramipril
AZIENDA OSPEDALIERA PROVINCIALE DI LECCO
2005 - EUCTR2005-003885-40-IT Italy
Chinese University of Hong Kong
2002 Phase 3 NCT01225445 Hong Kong
The Chinese University of Hong Kong
2004 - ChiCTR-TRC-09000630 China
Rapamune
NEPHROLOGY DEPARTMENT (HOSPITAL UNIVERSITARY OF BELLVITGE)
2005 - EUCTR2005-002610-37-ES Spain
RAS
Assistance Publique - Hôpitaux de Paris
2018 Phase 3 NCT03188887 France
Tianjin Hospital
2023 - ChiCTR2500101762 China
RAS 2410
Nan Chen,MD
2020 Phase 4 NCT04525729 China
RAS inhibitor
Ruijin Hospital
2023 - NCT06589752 China
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2022 - NCT06460987 China
Ravulizumab
ALEXION PHARMACEUTICALS INCORPORATED
2021 Phase 2 EUCTR2020-001537-13-IT Australia;Belgium;Canada;France;Germany;Italy;Korea, Democratic People's Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Alexion Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-001537-13-SE Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-FR Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-ES Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
2021 Phase 2 EUCTR2020-001537-13-DE Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Dr. Alfons Segarra Medrano
2022 Phase 4 EUCTR2021-005609-28-ES Spain
RC18 160MG
RemeGen Co., Ltd.
2020 Phase 2 NCT04291781 China
RC18 240MG
RemeGen Co., Ltd.
2020 Phase 2 NCT04291781 China
RE-021
RETROPHIN, INC
2018 Phase 3 EUCTR2017-004605-41-IT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Retrophin, Inc.
2018 Phase 3 EUCTR2017-004605-41-GB Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-ES Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States
TRAVERE THERAPEUTICS, INC
2022 Phase 2 EUCTR2021-000621-27-IT France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
Travere Therapeutics Inc.
2019 Phase 3 EUCTR2017-004605-41-PT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2019 Phase 3 EUCTR2017-004605-41-PL Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2019 Phase 3 EUCTR2017-004605-41-DE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-LT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-HR Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-EE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-CZ Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-BE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Travere Therapeutics, Inc.
2022 Phase 2 EUCTR2021-000621-27-SE France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
2022 Phase 2 EUCTR2021-000621-27-NL France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
2022 Phase 2 EUCTR2021-000621-27-FR France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
2021 Phase 2 EUCTR2021-000621-27-ES France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
- Phase 2 EUCTR2021-000621-27-PL France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
- Phase 2 EUCTR2021-000621-27-DE France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
University of Leicester
2019 Phase 2 EUCTR2018-002012-27-GB United Kingdom
REH-acteoside
Sun Yat-sen University
2016 Phase 2/Phase 3 NCT02662283 China
Risedronate
Osaka University Hospital Department of nephrology
2007 - JPRN-UMIN000002474 Japan
Rituximab
Nan Chen,MD
2020 Phase 4 NCT04525729 China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
2020 Phase 4 ChiCTR2000036468 China
SC0062 high dose
Biocity Biopharmaceutics Co., Ltd.
2023 Phase 2 NCT05687890 China
SC0062 LOW dose
Biocity Biopharmaceutics Co., Ltd.
2023 Phase 2 NCT05687890 China
SC0062 medium dose
Biocity Biopharmaceutics Co., Ltd.
2023 Phase 2 NCT05687890 China
SC0062 strength 10MG
Biocity Biopharmaceutics Co., Ltd.
2025 Phase 3 NCT06819826 China
SCTC21C
Sinocelltech Ltd.
2025 Phase 1/Phase 2 NCT06774664 China
SGB-9768
Suzhou Sanegene Bio Inc.
2025 Phase 2 NCT06786338 China
SHR-2010 injection
Guangdong Hengrui Pharmaceutical Co., Ltd
2023 Phase 2 NCT05847920 China
2022 Phase 1 NCT05398510 China
Sibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
2024 Phase 2 NCT06740526 Canada;United States
Simulect
Centre Hospitalier Universitaire de Saint Etienne
2011 Phase 4 NCT02523768 France
Simvastatin
Fukuoka University Faculty of Medicine
2009 - JPRN-UMIN000002887 Japan
Sirolimus
NEPHROLOGY DEPARTMENT (HOSPITAL UNIVERSITARY OF BELLVITGE)
2005 - EUCTR2005-002610-37-ES Spain
Peking Union Medical College Hospital
2022 Phase 4 ChiCTR2200066031 China
Sirolimus (study drug)+ACE inhibitor + statin
Josep m Cruzado
2006 Phase 2 NCT00396721 Spain
SM101
Baxalta Innovations GmbH
2015 - EUCTR2015-002345-64-CZ Belgium;Canada;Czech Republic;Denmark;Germany;Hong Kong;Sweden;United Kingdom;United States
Baxalta now part of Shire
2015 Phase 2 NCT02605525 -
Solu medrol - 1000 MG/16 ML polvere E solvente PER soluzione iniettabile 1 flacone DI polvere DA 1000 MG+ 1 flacone solvente DA 16 ML
Fondazione Schena - Centro Europeo della Ricerca sulle Malattie Renali
2022 Phase 3 EUCTR2021-006854-29-IT Italy
Sparsentan
Retrophin, Inc.
2018 Phase 3 EUCTR2017-004605-41-ES Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States
TRAVERE THERAPEUTICS, INC
2022 Phase 2 EUCTR2021-000621-27-IT France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
Travere Therapeutics, Inc.
2022 Phase 2 EUCTR2021-000621-27-SE France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
2022 Phase 2 EUCTR2021-000621-27-NL France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
2022 Phase 2 EUCTR2021-000621-27-FR France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
2021 Phase 2 EUCTR2021-000621-27-ES France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
2018 Phase 3 NCT03762850 Australia;Belgium;Croatia;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
- Phase 2 EUCTR2021-000621-27-PL France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
- Phase 2 EUCTR2021-000621-27-DE France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
University of Leicester
2019 Phase 2 EUCTR2018-002012-27-GB United Kingdom
Sparsentan compresse
RETROPHIN, INC
2018 Phase 3 EUCTR2017-004605-41-IT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Sparsentan tablets/OVER-encapsulated sparsentan tablets
Travere Therapeutics Inc.
2019 Phase 3 EUCTR2017-004605-41-PT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-LT Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-HR Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-EE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-CZ Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
2018 Phase 3 EUCTR2017-004605-41-BE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Sparsentan tablets/OVER-encapsulated spasenten tablets
Travere Therapeutics Inc.
2019 Phase 3 EUCTR2017-004605-41-PL Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Sparsentan tablets/overencapsulated sparsentan tablets
Retrophin, Inc.
2018 Phase 3 EUCTR2017-004605-41-GB Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Travere Therapeutics Inc.
2019 Phase 3 EUCTR2017-004605-41-DE Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States
Steroids plus azathioprine
A. Manzoni Hospital
1998 Phase 4 NCT00755859 Italy;Switzerland
Supportive and immunosuppressive therapy
RWTH Aachen University
2008 Phase 3 NCT00554502 Germany
Supportive therapy
RWTH Aachen
2008 - EUCTR2007-000871-41-DE Germany
Tianjin Hospital
2023 - ChiCTR2500101762 China
Supportive therapy with: ACE-inhibitor / ARB / statin
RWTH Aachen University
2008 Phase 3 NCT00554502 Germany
Tacrolimus
Astellas Pharma Inc
2010 Phase 2 NCT01224028 Korea, Republic of
Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University
2015 - ChiCTR-IPR-15006760 China
Tailored diet
Uppsala University Hospital
2010 - NCT01203007 Norway;Sweden
Tarpeyo 4 MG delayed release oral capsule
Ruijin Hospital
2023 - NCT06589752 China
Telitacicept
Ningxia Medical University General
2024 Phase 0 ChiCTR2400083794 China
RemeGen Co., Ltd.
2023 Phase 3 NCT05799287 China
Second Affiliated Hospital, School of Medicine, Zhejiang University
2023 Phase 2/Phase 3 NCT05596708 China
Shandong Provincial Hospital
2022 Phase 4 ChiCTR2200064790 China
The First Affiliated Hospital of Nanchang University
2024 Phase 4 ChiCTR2400092894 China
The Second Hospital of Shanxi Medical University
2024 - ChiCTR2400083991 China
Xijing hospital
2023 Phase 4 ChiCTR2300076949 China
Telitacicept 160MG
RemeGen Co., Ltd.
2021 Phase 2 NCT04905212 United States
West China Hospital of Sichuan University
2025 - ChiCTR2500096335 China
Telitacicept 240MG
Affiliated Hospital of North Sichuan Medical College
2024 Phase 0 ChiCTR2500098584 China
RemeGen Co., Ltd.
2021 Phase 2 NCT04905212 United States
Ruijin Hospital
2024 - NCT06654596 China
Telmisartan
Chinese General Hospital of PLA
2010 - ChiCTR-TRC-10000776 China
Xiyuan Hospital, China Academy of Chinese Medical Sciences
2021 - ChiCTR2100049833 China
2020 - ChiCTR2000040161 China
2019 - ChiCTR1900022100 China
Tetracycline
Tianjin Hospital
2023 - ChiCTR2500101762 China
THE YI-QI-QING-JIE herbal compound
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
2019 Phase 2/Phase 3 NCT03418779 China
Tofacitinib
Peking Union Medical College Hospital
2022 - ChiCTR2200066045 China
Tripterygium
Hangzhou Hospital of Traditional Chinese Medicine
2012 - ChiCTR-TRC-12002228 China
Nanjing University School of Medicine
2009 - NCT00885547 China
Second Xiangya Hospital of Central South University
2014 Phase 3 NCT02187900 China
Ultomiris
ALEXION PHARMACEUTICALS INCORPORATED
2021 Phase 2 EUCTR2020-001537-13-IT Australia;Belgium;Canada;France;Germany;Italy;Korea, Democratic People's Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Ultomiris 300 MG/30 ML
Dr. Alfons Segarra Medrano
2022 Phase 4 EUCTR2021-005609-28-ES Spain
Vaccino contro IL memingococco DI gruppo B
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Vaccino haemophilus influenzae B coniugato CON tossoidetetanico
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
Vaccino pneumococcico
NOVARTIS PHARMA AG
2022 Phase 3 EUCTR2020-002200-40-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam
2021 Phase 3 EUCTR2020-001049-38-IT Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam
Valsartan
ARB therapeutic society of IgA nephropathy
2003 Phase 4 JPRN-C000000380 Japan
Chinese Cardiovascular Association-HX Fund
2023 Phase 4 ChiCTR2300076082 China
Columbia University
2009 Phase 4 NCT01129557 United States
Guangdong General Hospital
2007 Phase 4 NCT00426348 China
Peking Union Medical College Hospital
2016 Phase 4 NCT02765594 China
Shanghai Dong Fang Hospital
2022 - ChiCTR2200063885 China
Shanghai East Hospital (East Hospital Affiliated to Tongji University)
2022 - ChiCTR2200062663 China
Shuguang Hospital affliliated to Shanghai Univesrity of TCM
2016 - ChiCTR-IOR-16010174 China
VIS649
Visterra, Inc.
2020 Phase 2 EUCTR2019-002531-29-GB Australia;Canada;Czech Republic;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Taiwan;Thailand;United Kingdom;United States
2018 Phase 1 NCT03719443 United States
VT-001
Vera Therapeutics, Inc.
2022 Phase 2 EUCTR2020-004892-41-PL Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-GR Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-DE Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-CZ Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
2021 Phase 2 EUCTR2020-004892-41-BE Australia;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States
Warfarin
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
2001 - JPRN-C000000363 Japan
1998 - JPRN-C000000374 Japan
The Japanese Pediatric IgA Nephropathy of Treatment Study Group
1998 - JPRN-C000000375 Japan
Water
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
2023 Phase 2 ChiCTR2400094993 China
Zigakibart
Novartis Pharmaceuticals
2025 Phase 3 NCT06858319 -